var title_f16_42_17056="Healing pubic ramus fractures";
var content_f16_42_17056=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F83967&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F83967&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Healing pubic ramus fractures",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 396px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This plain radiograph of the pelvis was obtained at the 6 week follow-up visit of an elder woman who sustained insufficiency fractures of the pubic rami. Not the callous formation (arrows) at the left superior pubic root and the the inferior pubic ramus fracture sites.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Jim Fiechtl, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f16_42_17056=[""].join("\n");
var outline_f16_42_17056=null;
var title_f16_42_17057="Laparoscopic mobilization of the ascending colon";
var content_f16_42_17057=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F83864&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F83864&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 521px\">",
"   <div class=\"ttl\">",
"    Laparoscopic mobilization of the ascending colon",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 501px; height: 375px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This picture shows the mobilization of the ascending colon in the avascular plane. This procedure is being performed laparoscopically.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f16_42_17057=[""].join("\n");
var outline_f16_42_17057=null;
var title_f16_42_17058="Transcription";
var content_f16_42_17058=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F67310&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F67310&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 614px\">",
"   <div class=\"ttl\">",
"    Gene transcription",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 594px; height: 709px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    (A) Genic structure.",
"    <br>",
"     (B) Transcription.",
"     <br>",
"      (C) Post-transcriptional modification.",
"      <div class=\"footnotes\">",
"      </div>",
"      <div class=\"reference\">",
"      </div>",
"     </br>",
"    </br>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f16_42_17058=[""].join("\n");
var outline_f16_42_17058=null;
var title_f16_42_17059="Betahistine: Drug information";
var content_f16_42_17059=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Betahistine: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?41/15/42227?source=see_link\">",
"    see \"Betahistine: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F140528\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      CO Betahistine;",
"     </li>",
"     <li>",
"      Novo-Betahistine;",
"     </li>",
"     <li>",
"      Serc&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F140561\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Histamine H",
"      <sub>",
"       1",
"      </sub>",
"      Agonist",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F140531\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     M&eacute;ni&egrave;re's disease: Oral: 8-16 mg 3 times/day or 24 mg twice daily",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F3062964\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F15682288\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment provided in manufacturer&rsquo;s labeling; use with caution.",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F15682289\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment provided in manufacturer&rsquo;s labeling.",
"    </p>",
"   </div>",
"   <div class=\"block foccan drugH1Div\" id=\"F8120616\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: Canada",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tablet, oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Novo-Betahistine: 8 mg, 16 mg, 24 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Serc&reg;: 16 mg, 24 mg",
"    </p>",
"   </div>",
"   <div class=\"block prod-avail drugH1Div\" id=\"F11217334\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Product Availability",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Not available in U.S.",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F140514\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Administration with meals is recommended.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F140513\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of M&eacute;ni&egrave;re's disease (to decrease episodes of vertigo)",
"    </p>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F140559\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     1% to 10%: Gastrointestinal: Dyspepsia, nausea",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Frequency not defined:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Headache, somnolence (case reports)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cardiovascular: Ventricular extrasystoles (case reports)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Dermatologic: Pruritus, rash, urticaria",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Abdominal bloating/distension, abdominal pain, peptic ulcer disease (including exacerbation of previous disease), vomiting",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Miscellaneous: Hypersensitivity (including anaphylaxis, angioedema)",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F140517\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to betahistine or any component of the formulation; peptic ulcer disease; pheochromocytoma",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F140503\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Cardiovascular disease: Use with caution in patients with cardiovascular disease.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Respiratory disease: Use with caution in patients with respiratory diseases, including asthma and COPD with bronchospastic component.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concurrent drug therapy issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Antihistamines: Avoid concurrent use with antihistamines.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13298856\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F140507\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antihistamines: May diminish the therapeutic effect of Betahistine.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Levocabastine (Nasal).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Beta2-Agonists: Betahistine may diminish the therapeutic effect of Beta2-Agonists.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F140519\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     There are no adequate and well-controlled studies in pregnant women. Should be used only when potential benefit to the woman outweighs possible risk to fetus.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F140533\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/use caution",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F16248949\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     It is not known if betahistine is excreted in breast milk. The manufacturer recommends that caution be exercised when administering betahistine to nursing women.",
"    </p>",
"   </div>",
"   <div class=\"block dic drugH1Div\" id=\"F140520\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dietary Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Should be taken with food.",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F140521\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Aequamen (DE);",
"     </li>",
"     <li>",
"      Agiserc (IL);",
"     </li>",
"     <li>",
"      Alfinor (HK, MY);",
"     </li>",
"     <li>",
"      Antivom (HK);",
"     </li>",
"     <li>",
"      Beautipex (KP);",
"     </li>",
"     <li>",
"      Behistin (TH);",
"     </li>",
"     <li>",
"      Betahistine-Eurogenerics (LU);",
"     </li>",
"     <li>",
"      Betaserc (AT, BE, BG, BR, CH, CZ, DK, EC, EE, FI, GR, HK, HN, HR, HU, ID, LU, MY, NL, NO, PE, PH, PL, PT, RU, SG, TR, TW);",
"     </li>",
"     <li>",
"      Betavert (PH);",
"     </li>",
"     <li>",
"      Betistin (UY);",
"     </li>",
"     <li>",
"      Clensan (TW);",
"     </li>",
"     <li>",
"      Exigo (PH);",
"     </li>",
"     <li>",
"      Fidium (ES);",
"     </li>",
"     <li>",
"      Histigo (ID);",
"     </li>",
"     <li>",
"      Lectil (FR);",
"     </li>",
"     <li>",
"      Lexigo (ID);",
"     </li>",
"     <li>",
"      Lobione (LU);",
"     </li>",
"     <li>",
"      Meniace (JP);",
"     </li>",
"     <li>",
"      Menistin (PE);",
"     </li>",
"     <li>",
"      Merislon (CL, CR, DO, GT, HK, ID, JP, MY, PH, SG, SV, TH, TW);",
"     </li>",
"     <li>",
"      Mertigo (ID, TH);",
"     </li>",
"     <li>",
"      Meslon (TW);",
"     </li>",
"     <li>",
"      Microser (AR, CN, IT, PE, PK, VE);",
"     </li>",
"     <li>",
"      Nisulin (TW);",
"     </li>",
"     <li>",
"      Rotaver (ID);",
"     </li>",
"     <li>",
"      Serc (AU, GB, IE, MX, NZ, PK, TH, ZA);",
"     </li>",
"     <li>",
"      Stei (TH);",
"     </li>",
"     <li>",
"      Suzutolon (JP);",
"     </li>",
"     <li>",
"      Urutal (HR);",
"     </li>",
"     <li>",
"      Vasomotal (DE, PY);",
"     </li>",
"     <li>",
"      Vasotal (UY);",
"     </li>",
"     <li>",
"      Verdiz (PH);",
"     </li>",
"     <li>",
"      Vergo (NZ);",
"     </li>",
"     <li>",
"      Vert (PH);",
"     </li>",
"     <li>",
"      Vertin (IN);",
"     </li>",
"     <li>",
"      Verum (CO)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F13121044\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Agonist of histamine at H",
"     <sub>",
"      1",
"     </sub>",
"     receptor and antagonist at H",
"     <sub>",
"      3",
"     </sub>",
"     receptor; relatively inactive at H",
"     <sub>",
"      2",
"     </sub>",
"     receptor. Animal studies suggest that betahistine may increase cochlear blood flow and produce excitatory effects on neuronal activity of cortical and subcortical structures via H",
"     <sub>",
"      1",
"     </sub>",
"     -receptor agonism and decrease vestibular sensory input and increase synthesis and release of histamine from the hypothalamus via H",
"     <sub>",
"      3",
"     </sub>",
"     -receptor antagonism (Lacour, 2007).",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F140516\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: Rapid, complete",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Hepatic",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination: 3.4 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Urine (as inactive metabolites)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Lacour M, van de Heyning PH, Novotny M, et al, &ldquo;Betahistine in the Treatment of M&eacute;ni&egrave;re&rsquo;s Disease,&rdquo;",
"      <i>",
"       Neuropsychiatr Dis Treat",
"      </i>",
"      , 2007, 3(4):429-40.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?16/42/17059/abstract-text/19300572/pubmed\" id=\"19300572\" target=\"_blank\">",
"        19300572",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 8694 Version 33.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0505-61.234.146.186-A1721555EE-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f16_42_17059=[""].join("\n");
var outline_f16_42_17059=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F140528\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F140561\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F140531\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3062964\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15682288\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15682289\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8120616\">",
"      Dosage Forms: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11217334\">",
"      Product Availability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F140514\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F140513\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F140559\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F140517\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F140503\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13298856\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F140507\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F140519\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F140533\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16248949\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F140520\">",
"      Dietary Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F140521\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13121044\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F140516\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8694\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8694|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?41/15/42227?source=related_link\">",
"      Betahistine: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f16_42_17060="Normal human band form";
var content_f16_42_17060=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=HEME%2F82140&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=HEME%2F82140&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Normal human band form",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 448px; height: 288px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Peripheral blood smear shows a normal human band form. The nucleus is nonsegmented and elongated resembling a horseshoe shape; there are no nuclear lobulations but a constriction is visible. The nuclear chromatin is aggregated into evenly arranged clumps. The cytoplasm is like the mature neutrophil with pink staining and fine azure bluish granules.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Robert L Baehner, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f16_42_17060=[""].join("\n");
var outline_f16_42_17060=null;
var title_f16_42_17061="Right phrenic nerve course";
var content_f16_42_17061=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F52959&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F52959&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 543px\">",
"   <div class=\"ttl\">",
"    Course of the right phrenic nerve",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 523px; height: 603px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f16_42_17061=[""].join("\n");
var outline_f16_42_17061=null;
var title_f16_42_17062="Emtricitabine: Pediatric drug information";
var content_f16_42_17062=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Emtricitabine: Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"UTD.htm?5/15/5366?source=see_link\">",
"    see \"Emtricitabine: Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?16/51/17205?source=see_link\">",
"    see \"Emtricitabine: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block black-box-warn drugH1Div\" id=\"F5708728\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     ALERT: U.S. Boxed Warning",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The FDA-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information.  For verbatim wording of the boxed warning, consult the product labeling or",
"     <a href=\"file://www.fda.gov\" target=\"_blank\">",
"      www.fda.gov",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F164630\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Emtriva&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F2948875\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Emtriva&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F1599159\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Antiretroviral Agent",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       HIV Agents (Anti-HIV Agents)",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Nucleoside Reverse Transcriptase Inhibitor (NRTI)",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block don drugH1Div\" id=\"F11442372\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Neonatal",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      HIV infection, treatment: Note:",
"     </b>",
"     Use in combination with other antiretroviral agents: Oral solution: 3 mg/kg/dose once daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Dosage adjustment in renal impairment:",
"     </b>",
"     Monitor clinical response and renal function closely. There are no dosage adjustments provided in the manufacturer&rsquo;s labeling (not studied); however, consider a reduction in the dose and/or an increase in the dosing interval similar to dosage adjustments for adults.",
"    </p>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F1599171\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"UTD.htm?5/15/5366?source=see_link\">",
"      see \"Emtricitabine: Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Infants, Children, and Adolescents:",
"     <b>",
"      HIV infection, treatment: Note:",
"     </b>",
"     Use in combination with other antiretroviral agents. Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Infants 1 to &lt;3 months: Oral solution: 3 mg/kg/dose once daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Infants &ge;3 months, Children, and Adolescents:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Oral solution: 6 mg/kg/dose once daily; maximum daily dose: 240 mg/",
"     <b>",
"      day",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Capsule: Patient weight &gt;33 kg and able to swallow capsule whole:  200 mg once daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Adolescents &ge;18 years and Adults:",
"     <b>",
"      HIV infection, treatment:",
"     </b>",
"     <b>",
"      Note:",
"     </b>",
"     Use in combination with other antiretroviral agents. Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Capsules: 200 mg once daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Oral solution: 240 mg once daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Dosage adjustment in renal impairment:",
"     </b>",
"     Monitor clinical response and renal function closely.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Infants, Children, and Adolescents &lt;18 years: There are no dosage adjustments provided in the manufacturer&rsquo;s labeling; however, may consider a reduction in the dose and/or an increase in the dosing interval similar to dosage adjustments for adults.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Adolescents &ge;18 years and Adults:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &ge; 50 mL/minute: No dosage adjustment necessary",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     30-49 mL/minute: Capsule: 200 mg every 48 hours; oral solution: 120 mg every 24 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     15-29 mL/minute: Capsule: 200 mg every 72 hours; oral solution: 80 mg every 24 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;15 mL/minute (including hemodialysis patients):",
"     <b>",
"      Note:",
"     </b>",
"     If dose is given on day of dialysis, administer dose after dialysis: Capsule: 200 mg every 96 hours; oral solution: 60 mg every 24 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Dosage adjustment in hepatic impairment:",
"     </b>",
"     There are no dosage adjustments provided in the manufacturer&rsquo;s labeling; however, emtricitabine is not metabolized by liver enzymes so the impact of liver impairment should be minimal; monitor patients closely.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F164606\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Capsule, oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Emtriva&reg;: 200 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Solution, oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Emtriva&reg;: 10 mg/mL (170 mL) [contains propylene glycol; cotton candy flavor]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F164593\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F1599172\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     May be administered without regard to food",
"    </p>",
"   </div>",
"   <div class=\"block sta drugH1Div\" id=\"F1599168\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Stability",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Capsules: Store at 25&deg;C (77&deg;F); excursions permitted to 15&deg;C to 30&deg;C (59&deg;F to 86&deg;F).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Oral solution: Store at 2&deg;C to 8&deg;C (36&deg;F to 46&deg;F). Use within 3 months if stored at 25&deg;C (77&deg;F) with excursions permitted to 15&deg;C to 30&deg;C (59&deg;F to 86&deg;F).",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F1599161\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of HIV infection in combination with other antiretroviral agents (FDA approved in all ages).",
"     <b>",
"      Note:",
"     </b>",
"     HIV regimens consisting of",
"     <b>",
"      three",
"     </b>",
"     antiretroviral agents are strongly recommended.",
"    </p>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F164653\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Abnormal dreams, depression, dizziness, headache, insomnia, neuropathy/neuritis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Hyperpigmentation (primarily of palms and/or soles but may include tongue, arms, lip and nails; generally mild and nonprogressive without associated local reactions such as pruritus or rash), rash (includes pruritus, maculopapular rash, vesiculobullous rash, pustular rash, and allergic reaction)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Disordered glucose homeostasis, serum amylase increased, serum triglycerides increased",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Abdominal pain, diarrhea, dyspepsia, nausea, serum amylase increased, vomiting",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Genitourinary: Hematuria",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hematologic: Anemia, neutropenia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hepatic: Alkaline phosphatase increased, bilirubin increased, transaminases  increased",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Arthralgia, CPK increased, creatinine kinase increased, myalgia, paresthesia, weakness",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Respiratory: Cough, respiratory tract infection (upper), pharyngitis, rhinitis, sinusitis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Rare but important or life-threatening: Immune reconstitution syndrome",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F1599163\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to emtricitabine or any component",
"    </p>",
"   </div>",
"   <div class=\"block pre drugH1Div\" id=\"F1599177\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Precautions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use with caution and reduce dosage in patients with impaired renal function. Fat redistribution and accumulation [ie, central obesity, peripheral wasting, facial wasting, breast enlargement, dorsocervical fat enlargement (buffalo hump), and cushingoid appearance] have been observed in patients receiving antiretroviral agents (causal relationship not established).",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Immune reconstitution syndrome (an acute inflammatory response to residual or indolent opportunistic infections) may occur in HIV patients during initial treatment with combination antiretroviral agents; this syndrome may require further patient assessment and therapy. Autoimmune disorders (eg, Grave&rsquo;s disease, Guillain-Barr&eacute; syndrome, and polymyositis) have been reported in patients experiencing immune reconstitution; time to onset is variable and may occur many months after antiretroviral treatment is initiated.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Hyperpigmentation may occur at a higher frequency in pediatric patients compared to adults [children: 32%; adults: 2% to 6% (may be higher in African-Americans)]; occurs primarily on palms and/or soles but may include tongue, arms, lips, and nails; generally mild, asymptomatic, nonprogressive, and without associated local reactions, such as pruritus or rash. Do not administer Emtriva&reg; with other emtricitabine-containing medications (eg, Atripla&reg;, Complera&reg;, Stribild&reg; or Truvada&reg;) or with medications that contain lamivudine (eg, Epivir&reg;, Epivir-HBV&reg;, Combivir&reg;, Epzicom&reg;, or Trizivir&reg;).",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F1599164\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Cases of lactic acidosis, severe hepatomegaly with steatosis, and death have been reported in patients receiving nucleoside analogues",
"     <b>",
"      [U.S. Boxed Warning]",
"     </b>",
"     ; most of these cases have been in women; prolonged nucleoside use, obesity, and prior liver disease may be risk factors; use with extreme caution in patients with other risk factors for liver disease; discontinue therapy in patients who develop laboratory or clinical evidence of lactic acidosis or pronounced hepatotoxicity. Safety and efficacy during coinfection of HIV and HBV have not been established; acute, severe exacerbations of HBV have been reported following discontinuation of antiretroviral therapy",
"     <b>",
"      [U.S. Boxed Warning]",
"     </b>",
"     ; monitor hepatic function closely for several months after discontinuation; initiate antihepatitis B therapy if needed. Not indicated for treatment of chronic hepatitis B. All patients with HIV should be tested for HBV prior to initiation of treatment. Use with caution in patients with known or suspected hepatitis B or C infection; monitoring of liver function is recommended.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299258\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F164600\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ganciclovir-Valganciclovir: May enhance the adverse/toxic effect of Reverse Transcriptase Inhibitors (Nucleoside). Hematologic toxicity is of specific concern.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     LamiVUDine: May enhance the adverse/toxic effect of Emtricitabine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ribavirin: May enhance the hepatotoxic effect of Reverse Transcriptase Inhibitors (Nucleoside). Lactic acidosis may occur.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F1599167\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Food Interactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Capsules: A high fat meal decreases peak plasma concentrations, but not the extent of absorption (AUC not affected)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Oral solution: Neither a high-fat nor a low-fat meal affected peak plasma concentrations or AUC",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F164602\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     B (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F164615\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adverse events were not observed in animal studies. Emtricitabine crosses the placenta; no increased risk of overall birth defects has been observed according to data collected by the antiretroviral pregnancy registry. Cases of lactic acidosis/hepatic steatosis syndrome related to mitochondrial toxicity have been reported in pregnant women with prolonged use of nucleoside analogues. It is not known if pregnancy itself potentiates this known side effect; however, women may be at increased risk of lactic acidosis and liver damage. In addition, these adverse events are similar to other rare but life-threatening syndromes which occur during pregnancy (eg, HELLP syndrome). Hepatic enzymes and electrolytes should be monitored in women receiving nucleoside analogues and clinicians should watch for early signs of the syndrome. In addition, mitochondrial dysfunction may develop in infants following",
"     <i>",
"      in utero",
"     </i>",
"     exposure.  A pharmacokinetic study shows a slight decrease in emtricitabine serum levels during the third trimester; however, there is no clear need to adjust the dose. The DHHS Perinatal HIV Guidelines consider emtricitabine to be an alternative NRTI in dual nucleoside combination regimens. The DHHS Perinatal HIV Guidelines consider emtricitabine plus tenofovir a recommended dual NRTI/NtRTI backbone for HIV/HBV coinfected pregnant women.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Regardless of CD4 count or HIV RNA copy number, all HIV-infected pregnant women should receive a combination antepartum antiretroviral (ARV) drug regimen; this includes women who require therapy for their own health, as well as women who do not yet require therapy for their own health. ARV therapy should be started as soon as possible if required for the woman&rsquo;s health. Although earlier initiation may be more effective in reducing the perinatal transmission of HIV, also consider maternal conditions (eg, nausea and vomiting) and the potential risks of first trimester fetal exposure for specific agents. Plasma HIV RNA levels should be assessed at ~34-36 weeks gestation in order to help determine mode of delivery. If ARV therapy must be interrupted for &lt;24 hours during the peripartum period, stop then restart all medications simultaneously in order to decrease the chance of developing resistance. Long-term follow-up is recommended for all infants exposed to ARV medications.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Healthcare providers are encouraged to enroll pregnant women exposed to antiretroviral medications in the Antiretroviral Pregnancy Registry (1-800-258-4263 or www.APRegistry.com). Healthcare providers caring for HIV-infected women and their infants may contact the National Perinatal HIV Hotline (888-448-8765) for clinical consultation (DHHS [perinatal], 2012).",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F1599173\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Note:",
"     </b>",
"     Monitor CD4 percentage (if &lt;5 years of age) or CD4 count (if &ge;5 years of age) at least every 3-4 months (DHHS [pediatric], 2012)",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Patients should be screened for hepatitis B infection before starting therapy. Prior to initiation of therapy: Genotypic resistance testing, CD4, viral load, CBC with differential, LFTs, BUN, creatinine. At initiation and with any change in treatment regimen: CBC with differential, electrolytes, calcium, phosphorus, glucose, LFTs, bilirubin, BUN, creatinine, albumin, total protein, lipid panel, CD4, and viral load.  After 4-8 weeks of therapy: CBC with differential, viral load; then every 3-4 months: CBC with differential, electrolytes, glucose, LFTs, bilirubin, BUN, creatinine, CD4 and viral load. Albumin, total protein, lipid panel and urinalysis every 6-12 months (DHHS [pediatric], 2012). Monitor for signs of opportunistic infections, lactic acidosis, or hyperpigmentation.",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F1599169\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     A synthetic nucleoside analogue that is phosphorylated by intracellular kinases to the active triphosphate metabolite (emtricitabine 5'-triphosphate) which inhibits HIV-1 reverse transcription via viral DNA chain termination after incorporation of the nucleoside analogue. Emtricitabine triphosphate is a weak inhibitor of mammalian DNA polymerase alpha-, beta-, epsilon- and mitochondrial DNA polymerase gamma.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F1599170\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacokinetics (Adult data unless noted)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: Rapid, extensive",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: &lt;4%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Converted intracellularly to the active triphosphate form; undergoes minimal biotransformation via oxidation and glucuronide conjugation",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Bioavailability:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Capsules: 93%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Oral solution: 75%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <b>",
"      Note:",
"     </b>",
"     Relative bioavailability of solution to capsule: 80%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life: Normal renal function:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Infants, Children, and Adolescents: Elimination half-life (emtricitabine):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Single dose: 11 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Multiple dose: 7.9-9.5 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Infants 0-3 months (n=20; median age: 26 days): 12.1 &plusmn; 3.1 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Infants 3-24 months (n=14): 8.9 &plusmn; 3.2 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Children 25 months to 6 years (n=19): 11.3 &plusmn; 6.4 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Children 7-12 years (n=17): 8.2 &plusmn; 3.2 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Adolescents 13-17 years (n=27): 8.9 &plusmn; 3.3 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Adults:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Elimination half-life (emtricitabine): 10 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Intracellular half-life (emtricitabine 5'-triphosphate): 39 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak serum concentration: 1-2 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Elimination: Urine (86% of dose, primarily as unchanged drug; 13% as metabolites; 9% of dose as oxidative metabolite; 4% as glucuronide metabolite); feces (14% of dose)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Clearance: Renal clearance is greater than creatinine clearance; thus, emtricitabine may be eliminated by both glomerular filtration and active tubular secretion",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dialysis: 30% of the dose is removed by hemodialysis (over 3 hours)",
"    </p>",
"   </div>",
"   <div class=\"block pai drugH1Div\" id=\"F1606084\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Patient Information",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?16/51/17205?source=see_link\">",
"      see \"Emtricitabine: Patient drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Emtricitabine is not a cure for HIV. Notify physician if persistent severe abdominal pain, nausea, vomiting, rash, numbness, or tingling occur. May cause dizziness and impair ability to perform activities requiring mental alertness or physical coordination. Take emtricitabine every day as prescribed; do not change dose or discontinue without physician's advice; if a dose is missed, take it as soon as possible, then return to normal dosing schedule; if a dose is skipped, do",
"     <b>",
"      not",
"     </b>",
"     double the next dose.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     HIV medications may cause changes in body fat, including an increase in fat in the upper back and neck, breasts, and trunk; a loss of fat from the face, arms, and legs may also occur. Some HIV medications (including emtricitabine) may cause a serious, but rare, condition called lactic acidosis with an increase in liver size (hepatomegaly). Before starting emtricitabine, inform physician about medical conditions, including any liver or kidney problems. Do not take Emtriva&reg; with other emtricitabine-containing medications (eg, Atripla&reg;, Complera&reg;, Stribild&reg;, or Truvada&reg;) or with medications that contain lamivudine (eg, Epivir&reg;, Epivir-HBV&reg;, Combivir&reg;, Epzicom&reg;, or Trizivir&reg;).",
"    </p>",
"   </div>",
"   <div class=\"block adi drugH1Div\" id=\"F1606085\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Additional Information",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Emtricitabine is the (-) enantiomer of 2', 3'-dideoxy-5-fluoro-3'-thiacytidine (FTC), a fluorinated derivative of lamivudine.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Mutation in the HIV reverse transcriptase gene at codon 184, M184V/I (ie, substitution of methionine by valine or isoleucine) is associated with resistance to emtricitabine. Emtricitabine-resistant isolates (M184V/I) are cross-resistant to lamivudine and zalcitabine. HIV-1 isolates containing the K65R mutation show reduced susceptibility to emtricitabine.",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Bang LM and Scott LJ, \"Emtricitabine: An Antiretroviral Agent for HIV Infection,\"",
"      <i>",
"       Drugs",
"      </i>",
"      , 2003, 63(22):2413-24.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?16/42/17062/abstract-text/14609348 /pubmed\" id=\"14609348 \" target=\"_blank\">",
"        14609348",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      DHHS Panel on Antiretroviral Guidelines for Adults and Adolescents, \"Guidelines for the Use of Antiretroviral Agents in HIV-Infected Adults and Adolescents,\" February 12, 2013. Available at",
"      <a href=\"file://www.aidsinfo.nih.gov\" target=\"_blank\">",
"       file://www.aidsinfo.nih.gov",
"      </a>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      DHHS Panel on Antiretroviral Therapy and Medical Management of HIV-Infected Children, \"Guidelines for the Use of Antiretroviral Agents in Pediatric HIV Infection,\" November 5, 2012. Available at",
"      <a href=\"file://aidsinfo.nih.gov\" target=\"_blank\">",
"       file://aidsinfo.nih.gov",
"      </a>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      DHHS Panel on Treatment of HIV-Infected Pregnant Women and Prevention of Perinatal Transmission, \"Recommendations for the Use of Antiretroviral Drugs in Pregnant HIV-1-Infected Women for Maternal Health and Interventions to Reduce Perinatal HIV-1 Transmission in the United States,\" July 31, 2012. Available at",
"      <a href=\"file://aidsinfo.nih.gov\" target=\"_blank\">",
"       file://aidsinfo.nih.gov",
"      </a>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Frampton JE and Perry CM, \"Emtricitabine: A Review of Its Use in the Management of HIV Infection,\"",
"      <i>",
"       Drugs",
"      </i>",
"      , 2005, 65(10):1427-48.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?16/42/17062/abstract-text/15977972/pubmed\" id=\"15977972\" target=\"_blank\">",
"        15977972",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Morris JL and Kraus DM, \"New Antiretroviral Therapies for Pediatric HIV Infection,\"",
"      <i>",
"       J Pediatr Pharmacol Ther",
"      </i>",
"      , 2005, 10:215-47.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Wang LH, Wiznia AA, Rathore MH, et al, \"Pharmacokinetics and Safety of Single Oral Doses of Emtricitabine in Human Immunodeficiency Virus-Infected Children,\"",
"      <i>",
"       Antimicrob Agents Chemother",
"      </i>",
"      , 2004, 48(1):183-91.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?16/42/17062/abstract-text/14693538/pubmed\" id=\"14693538\" target=\"_blank\">",
"        14693538",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 13245 Version 35.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1105-122.72.76.133-94E968098A-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f16_42_17062=[""].join("\n");
var outline_f16_42_17062=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5708728\">",
"      ALERT: U.S. Boxed Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F164630\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2948875\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1599159\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11442372\">",
"      Dosing: Neonatal",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1599171\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F164606\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F164593\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1599172\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1599168\">",
"      Stability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1599161\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F164653\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1599163\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1599177\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1599164\">",
"      Warnings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299258\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F164600\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1599167\">",
"      Food Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F164602\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F164615\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1599173\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1599169\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1599170\">",
"      Pharmacokinetics (Adult data unless noted)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1606084\">",
"      Patient Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1606085\">",
"      Additional Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/13245\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/13245|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?5/15/5366?source=related_link\">",
"      Emtricitabine: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?16/51/17205?source=related_link\">",
"      Emtricitabine: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f16_42_17063="Vandetanib: Drug information";
var content_f16_42_17063=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Vandetanib: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?10/52/11078?source=see_link\">",
"    see \"Vandetanib: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block black-box-warn drugH1Div\" id=\"F12745724\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     ALERT: U.S. Boxed Warning",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The FDA-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information.  For verbatim wording of the boxed warning, consult the product labeling or",
"     <a href=\"file://www.fda.gov\" target=\"_blank\">",
"      www.fda.gov",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F13034485\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Caprelsa&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F13812981\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Caprelsa&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F12731673\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Antineoplastic Agent, Tyrosine Kinase Inhibitor;",
"     </li>",
"     <li>",
"      Epidermal Growth Factor Receptor (EGFR) Inhibitor;",
"     </li>",
"     <li>",
"      Vascular Endothelial Growth Factor (VEGF) Inhibitor",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F12746079\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Note:",
"     </b>",
"     Do not initiate treatment unless QTcF &lt;450 msec. Avoid concomitant use of QT-prolonging agents and strong CYP3A4 inducers. To reduce the risk of QT prolongation, maintain serum calcium and magnesium within normal limits and maintain serum potassium &ge;4 mEq/L.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">",
"     <b>",
"      Medullary thyroid cancer, locally advanced or metastatic:",
"     </b>",
"     Oral: 300 mg once daily, continue treatment until no longer clinically benefiting or until unacceptable toxicity",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F12746080\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F12746081\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &ge;50 mL/minute: No dosage adjustment necessary.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;50 mL/minute: Reduce initial dose to 200 mg once daily; closely monitor QT interval.",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F12746082\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mild impairment: No dosage adjustment provided in manufacturer's labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Moderate and severe impairment (Child-Pugh class B or C): Use is not recommended.",
"    </p>",
"   </div>",
"   <div class=\"block dot drugH1Div\" id=\"F12746096\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adjustment for Toxicity",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     QTcF &gt;500 msec: Withhold dose until QTcF returns to &lt;450 msec, then resume at a reduced dose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Toxicity &ge;grade 3: Interrupt dose until resolves or improves to grade 1, then resume at a reduced dose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <i>",
"      Dosage reduction:",
"     </i>",
"     Reduce from 300 mg once daily to 200 mg once daily, further reduce if needed to 100 mg once daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">",
"     <b>",
"      Management of specific toxicities:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">",
"     Diarrhea (severe): Withhold treatment until resolution. Dose reduction is recommended when treatment is resumed. Routine antidiarrheals are recommended. Closely monitor electrolytes.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">",
"     Heart failure: May require discontinuation.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">",
"     Hemorrhage (severe): Discontinue.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">",
"     Hypertension: Initiate or adjust antihypertensive therapy as needed; may require vandetanib dosage adjustment or treatment interruption; discontinue permanently if blood pressure cannot be adequately controlled.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">",
"     Interstitial lung disease (ILD)/pneumonitis: If asymptomatic (or minimal symptoms) with radiologic evidence of ILD, may continue treatment with close monitoring. Consider interrupting treatment for moderate symptoms (may require corticosteroids or antibiotics). Discontinue treatment for severe symptoms; may require corticosteroids and antibiotics, and even permanent discontinuation.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">",
"     Ischemic cerebrovascular events (severe): Discontinue treatment (safety of resuming treatment after an ischemic event has not been studied).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">",
"     Reversible posterior leukoencephalopathy syndrome (RPLS): Consider discontinuing treatment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">",
"     Skin reactions: Withhold treatment for dermatologic toxicity of grade 3 or higher. Consider a reduced dose or permanent discontinuation upon improvement in symptoms. Severe dermatologic toxicity has been managed with corticosteroids (systemic) and treatment discontinuation; mild-to-moderate toxicity has responded to corticosteroids (systemic or topical), oral antihistamines, and antibiotics (topical or systemic).",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F12747281\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral: 100 mg, 300 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Caprelsa&reg;: 100 mg, 300 mg",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F12745731\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block accres drugH1Div\" id=\"F12745729\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Prescribing and Access Restrictions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     As a requirement of the REMS program, access to vandetanib is restricted. Vandetanib is approved for marketing under a Food and Drug Administration (FDA) approved, risk management program, and through a restricted distribution program, the Vandetanib REMS Program (1-800-236-9933). Prescribers and pharmacies must be certified with the program to prescribe or dispense vandetanib.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     In Canada, vandetanib is available only through the CAPRELSA Restricted Distribution Program. Prescribers and pharmacies must be certified with the program to prescribe or dispense vandetanib. Further information may be obtained at 1-800-668-6000.",
"    </p>",
"   </div>",
"   <div class=\"block meg drugH1Div\" id=\"F12745725\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Guide",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     An FDA-approved patient medication guide, which is available with the product information and at",
"     <a href=\"file://www.fda.gov/downloads/Drugs/DrugSafety/UCM250399.pdf\" target=\"_blank\">",
"      file://www.fda.gov/downloads/Drugs/DrugSafety/UCM250399.pdf",
"     </a>",
"     , must be dispensed with this medication.",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F12747206\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     May be administered with or without food. Missed doses should be omitted if within 12 hours of the next scheduled dose. Do not crush tablet. If unable to swallow tablet whole or if nasogastric or gastrostomy tube administration is necessary, disperse one tablet in 2 ounces of water (noncarbonated only) and stir for 10 minutes to disperse (will not dissolve completely) and administer immediately. Rinse residue in glass with additional 4 ounces of water (noncarbonated only) and administer.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Hazardous agent; use appropriate precautions for handling and disposal",
"     <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"      (meets NIOSH, 2012 criteria)",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F12731675\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of metastatic or unresectable locally advanced medullary thyroid cancer (symptomatic or progressive)",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F12731671\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Vandetanib may be confused with axitinib, dasatinib, erlotinib, gefitinib, imatinib, lapatinib, nilotinib, pazopanib, SORAfenib, SUNItinib, vemurafenib, vismodegib",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      High alert medication:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       This medication is in a class the Institute for Safe Medication Practices (ISMP) includes among its list of drug classes which have a heightened risk of causing significant patient harm when used in error.",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F12746025\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     &gt;10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Cardiovascular: Hypertension (33%; grades 3/4: 9%), QT prolongation (14%; grades 3/4: 8%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Central nervous system: Headache (26%), fatigue (24%), insomnia (13%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Dermatologic: Rash (53%; grades 3/4: 5%), dermatitis acneiform/acne (35%; grades 3/4: 1%), dry skin (15%), photosensitivity (13%), pruritus (11%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Endocrine &amp; metabolic: Hypocalcemia (11% to 57%), hypoglycemia (24%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Gastrointestinal: Diarrhea/colitis (57%; grades 3/4: 11%), nausea (33%), abdominal pain (21%), appetite decreased (21%), vomiting (15%), dyspepsia (11%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Hematologic: Leukopenia (19%), anemia (13%; grades 3/4: &lt;1%), hemorrhage (13% to 14%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Hepatic: ALT increased (51%), bilirubin increased (13%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Neuromuscular &amp; skeletal: Weakness (15%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Ocular: Corneal abnormalities (corneal edema, corneal opacity, corneal dystrophy, corneal pigmentation, keratopathy, arcus lipoides, corneal deposits, acquired corneal dystrophy: 13%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Renal: Creatinine increased (16%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Respiratory: Upper respiratory tract infection (23%), cough (11%), nasopharyngitis (11%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     1% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Cardiovascular: Cardiac failure (2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Central nervous system: Depression (10%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Dermatologic: Nail disorder (inflammation, tenderness, paronychia: 9%), alopecia (8%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Endocrine &amp; metabolic: Hypercalcemia (7%), hypomagnesemia (7%), hyperkalemia (6%), hypokalemia (6%), hyperglycemia (5%), hypermagnesemia (3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Gastrointestinal: Weight loss (10%), xerostomia (9%), abnormal taste (8%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Hematologic: Neutropenia (10%; grades 3/4: &lt;1%), thrombocytopenia (9%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Neuromuscular &amp; skeletal: Muscle spasms (6%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Ocular: Blurred vision (9%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Renal: Proteinuria (10%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Respiratory: Aspiration pneumonia (2%), respiratory arrest (2%), respiratory failure (2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Miscellaneous: Sepsis (2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     &lt;1% (Limited to important or life-threatening): Cardiopulmonary arrest, heart failure, interstitial lung disease, ischemic cerebrovascular events, palmar-plantar erythrodysesthesia syndrome, pancreatitis, pneumonitis, reversible posterior leukoencephalopathy syndrome (RPLS), Stevens-Johnson syndrome, torsade de pointes, ventricular tachycardia",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F12745737\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Congenital long QT syndrome",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Canadian labeling: Additional contraindications (not in U.S. labeling): Hypersensitivity to vandetanib or any component of the formulation; persistent Fridericia-corrected QT interval (QTcF) &ge;500 ms; uncorrected hypokalemia, hypomagnesemia, or hypocalcemia; uncontrolled hypertension",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F12745738\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Diarrhea: Diarrhea has been reported with use; may cause electrolyte imbalance (closely monitor electrolytes). Routine antidiarrheals are recommended. Withhold treatment until resolution for severe diarrhea; dose reduction is recommended when treatment is resumed.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Heart failure: Heart failure (HF) has been reported; monitor for signs and symptoms of HF. May require discontinuation. HF may not be reversible upon discontinuation.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hemorrhage: Serious and sometimes fatal hemorrhagic events have been reported with use. Discontinue in patients with severe hemorrhage.  Do not administer in patients with a recent history of hemoptysis with &ge;2.5 mL of red blood.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hypertension: Hypertension and hypertensive crisis have been observed with vandetanib. Monitor blood pressure and initiate or adjust antihypertensive therapy as needed. May require vandetanib dosage adjustment or treatment interruption; discontinue vandetanib (permanently) if blood pressure cannot be adequately controlled. Canadian labeling contraindicates use in uncontrolled hypertension.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hypothyroidism: Increased doses of thyroid replacement therapy have been required in patients with prior thyroidectomy. Obtain TSH at baseline, at 2-4 weeks, 8-12 weeks and every 3 months after vandetanib initiation. If signs and symptoms of hypothyroidism occur during treatment, evaluate thyroid hormone levels and adjust replacement therapy if needed.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Ischemic events: Ischemic cerebrovascular events (some fatal) have been observed with vandetanib. Discontinue treatment in patients with severe ischemic events. The safety of resuming treatment after an ischemic event has not been studied.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Pulmonary toxicity: Interstitial lung disease (ILD) or pneumonitis (including fatalities) has been reported with vandetanib. Patients should be advised to report any new or worsening respiratory symptoms; ILD should be suspected with nonspecific respiratory symptoms such as hypoxia, pleural effusion, cough or dyspnea. If asymptomatic (or minimal symptoms) although with radiologic evidence of ILD, may continue treatment with close monitoring; consider interrupting treatment for moderate symptoms (may require corticosteroids or antibiotics). Discontinue treatment for severe symptoms; may require corticosteroids and antibiotics, and permanent discontinuation.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; QT prolongation/sudden death:",
"     <b>",
"      [U.S. Boxed Warning]: May prolong the QT interval; torsade de pointes and sudden death have been reported. Do not use in patients with hypocalcemia, hypokalemia, hypomagnesemia, or long QT syndrome. Correct electrolyte imbalance prior to initiating therapy. Monitor electrolytes and ECG (to monitor QT interval) at baseline, at 2-4 weeks, at 8-12 weeks, and every 3 months thereafter; monitoring (at the same frequency) is required following dose reductions for QT prolongation or with dose interruptions &gt;2 weeks. Avoid the use of QT-prolonging agents; if concomitant use with QT prolonging agents cannot be avoided, monitor ECG more frequently. Vandetanib has a long half-life (19 days), therefore, adverse reactions (including QT prolongation) may resolve slowly; monitor appropriately.",
"     </b>",
"     Ventricular tachycardia has also been reported. The potential for QT prolongation is dose dependent. Do not initiate treatment unless Fridericia-corrected QT interval (QTcF) is &lt;450 msec. During treatment, if QTcF &gt;500 msec, withhold vandetanib and resume at a reduced dose when QTcF is &lt;450 msec. Avoid use in patients with a history of torsade de pointes, congenital long QT syndrome, bradyarrhythmias, or uncompensated heart failure. Patients with ventricular arrhythmias or recent MI were excluded from clinical trials. To reduce the risk of QT prolongation, maintain serum calcium and magnesium within normal limits and maintain serum potassium &ge;4 mEq/L.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Reversible posterior leukoencephalopathy syndrome (RPLS): RPLS been observed with vandetanib. Symptoms of RPLS include altered mental function, confusion, headache, seizure, or visual disturbances; generally associated with hypertension. Consider discontinuing treatment if RPLS occurs.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Skin reactions: Stevens-Johnson syndrome and other serious skin reactions (including fatal) have been reported. Mild-to-moderate skin reactions, including acne, dermatitis, dry skin, palmar-plantar erythrodysesthesia syndrome, pruritus, and rash have also been reported. Withhold treatment for dermatologic toxicity of grade 3 or higher; consider a reduced dose or permanent discontinuation upon improvement in symptoms. Severe dermatologic toxicity has been managed with corticosteroids (systemic) and treatment discontinuation; mild-to-moderate toxicity has responded to corticosteroids (systemic or topical), oral antihistamines, and antibiotics (topical or systemic). Increased risk of photosensitivity is associated  with vandetanib; effective sunscreen and protective clothing are recommended during and for at least 4 months after treatment discontinuation.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatic impairment: Data is limited; a single-dose pharmacokinetic study demonstrated comparable mean vandetanib AUC and clearance between healthy patients and hepatically impaired (mild-severe) patients. Manufacturer labeling does not provide specific recommendations in mild impairment; not recommended for use in patients with moderate-to-severe hepatic impairment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Renal impairment: Dosage reduction is recommended in patients with moderate-to-severe renal impairment. Exposure is increased in patients with impaired renal function; closely monitor QT interval. Has not been studied in patients with end stage renal disease requiring dialysis.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concurrent drug therapy issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; CYP3A4 inducers: Avoid concurrent use with strong CYP3A4 inducers, including St John&rsquo;s wort.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; QT-prolonging agents: Avoid concurrent use with QT-prolonging agents.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Special handling:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hazardous agent: Use appropriate precautions for handling and disposal",
"     <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"      (meets NIOSH, 2012 criteria)",
"     </a>",
"     .",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Appropriate use: Due to the risk for serious treatment-related adverse events, use in patients whose disease is not progressive or symptomatic should be only be undertaken after careful consideration.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Restricted access:",
"     <b>",
"      [U.S. Boxed Warning]: Vandetanib is only available through a restricted access program; prescribers and pharmacies must be certified with the restricted distribution program to prescribe and dispense vandetanib.",
"     </b>",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13300206\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Substrate",
"     </b>",
"     of CYP3A4 (major);",
"     <b>",
"      Note:",
"     </b>",
"     Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential;",
"     <b>",
"      Inhibits",
"     </b>",
"     BCRP, P-glycoprotein",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F12770227\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bosutinib: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Bosutinib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cardiac Glycosides: Antineoplastic Agents may decrease the absorption of Cardiac Glycosides. This may only affect digoxin tablets.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Digitoxin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Colchicine: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Colchicine. Colchicine distribution into certain tissues (e.g., brain) may also be increased.  Management: Colchicine is contraindicated in patients with impaired renal or hepatic function who are also receiving a p-glycoprotein inhibitor.  In those with normal renal and hepatic function, reduce colchicine dose as directed.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inducers (Strong): May decrease the serum concentration of Vandetanib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dabigatran Etexilate: P-glycoprotein/ABCB1 Inhibitors may increase serum concentrations of the active metabolite(s) of Dabigatran Etexilate.  Management: Dabigatran dose reductions may be needed.  Specific recommendations vary considerably according to US vs Canadian labeling, specific P-gp inhibitor, renal function, and indication for dabigatran treatment.  Refer to full monograph or dabigatran labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Deferasirox: May decrease the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Everolimus: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Everolimus.  Management: Everolimus dose reductions are required for patients being treated for subependymal giant cell astrocytoma or renal cell carcinoma.  See prescribing information for specific dose adjustment and monitoring recommendations.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Highest Risk QTc-Prolonging Agents: May enhance the QTc-prolonging effect of other Highest Risk QTc-Prolonging Agents.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ivabradine: May enhance the QTc-prolonging effect of Highest Risk QTc-Prolonging Agents.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mifepristone: May enhance the QTc-prolonging effect of Highest Risk QTc-Prolonging Agents.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Moderate Risk QTc-Prolonging Agents: May enhance the QTc-prolonging effect of Highest Risk QTc-Prolonging Agents.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     P-glycoprotein/ABCB1 Substrates: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of P-glycoprotein/ABCB1 Substrates. P-glycoprotein inhibitors may also enhance the distribution of p-glycoprotein substrates to specific cells/tissues/organs where p-glycoprotein is present in large amounts (e.g., brain, T-lymphocytes, testes, etc.).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pomalidomide: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Pomalidomide.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Prucalopride: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Prucalopride.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     QTc-Prolonging Agents (Indeterminate Risk and Risk Modifying): May enhance the QTc-prolonging effect of Highest Risk QTc-Prolonging Agents. Management: Avoid such combinations when possible.  Use should be accompanied by close monitoring for evidence of QT prolongation or other alterations of cardiac rhythm.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rivaroxaban: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Rivaroxaban.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Silodosin: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Silodosin.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     St Johns Wort: May decrease the serum concentration of Vandetanib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tocilizumab: May decrease the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Topotecan: BCRP/ABCG2 Inhibitors may increase the serum concentration of Topotecan.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     VinCRIStine (Liposomal): P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of VinCRIStine (Liposomal).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vitamin K Antagonists (eg, warfarin): Antineoplastic Agents may enhance the anticoagulant effect of Vitamin K Antagonists. Antineoplastic Agents may diminish the anticoagulant effect of Vitamin K Antagonists.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F12746057\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Herb/Nutraceutical: Avoid St John&rsquo;s wort (may decrease vandetanib exposure).",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F12745733\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     D (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F12745734\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Animal reproduction studies have demonstrated teratogenic effects and fetal loss. Because vandetanib inhibits angiogenesis, a critical component of fetal development, adverse effects on pregnancy would be expected. Women of childbearing potential should be advised to avoid pregnancy during and for 4 months following treatment with vandetanib. Canadian labeling recommends that nonsterile males employ reliable contraceptive methods (barrier method in conjunction with spermicide) during and for 2 months after vandetanib treatment.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F12745735\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/not recommended",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F12745736\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Due to the potential for serious adverse reactions in the nursing infant, breast-feeding is not recommended.",
"    </p>",
"   </div>",
"   <div class=\"block dic drugH1Div\" id=\"F12747205\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dietary Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     May be taken with or without food.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F16322896\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Caprelsa Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     100 mg (30): $6118.20",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     300 mg (30): $12236.40",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F12747267\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Monitor electrolytes (calcium, magnesium, potassium), TSH, and ECG (QT interval) at baseline, at 2-4 weeks, at 8-12 weeks, and every 3 months thereafter; also monitor QT interval at same frequency for dose reduction due to QT interval or treatment delays &gt;2 weeks (monitor electrolytes and ECG more frequently if diarrhea). Monitor renal function, hepatic function, blood pressure; monitor for signs and symptoms of heart failure and pulmonary toxicities.",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F14721649\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Caprelsa (CZ, DK, EE, GB, SE)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F12746060\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Multikinase inhibitor; inhibits tyrosine kinases including epidermal growth factor reception (EGFR), vascular endothelial growth factor (VEGF), rearranged during transfection (RET), protein tyrosine kinase 6 (BRK), TIE2, EPH kinase receptors and SRC kinase receptors, selectively blocking intracellular signaling, angiogenesis and cellular proliferation",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F12746062\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Absorption: Slow",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Protein binding: ~90%; to albumin and alpha 1-acid-glycoprotein",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Distribution: V",
"     <sub>",
"      d",
"     </sub>",
"     : ~7450 L",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metabolism: Hepatic, via CYP3A4 to N-desmethyl vandetanib and via flavin-containing monooxygenase enzymes to vandetanib-N-oxide",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bioavailability: Not affected by food",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Half life, elimination: 19 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Time to peak: 6 hours (range: 4-10 hours)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Excretion: Feces (~44%); urine (~25%)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      National Comprehensive Cancer Network&reg; (NCCN), &ldquo;Clinical Practice Guidelines in Oncology&trade;: Thyroid Carcinoma,&rdquo; Version 1.2011. Available at file://www.nccn.org/professionals/physician_gls/PDF/thyroid.pdf",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      National Institute for Occupational Safety and Health (NIOSH), \"NIOSH List of Antineoplastic and Other Hazardous Drugs in Healthcare Settings 2012.\" Available at",
"      <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"       file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf",
"      </a>",
"      . Accessed January 21, 2013.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Robinson BG, Paz-Ares L, Krebs A, et al, &ldquo;Vandetanib (100 mg) in Patients With Locally Advanced or Metastatic Hereditary Medullary Thyroid Cancer,&rdquo;",
"      <i>",
"       J Clin Endocrinol Metab",
"      </i>",
"      , 2010, 95(6):2664-71.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?16/42/17063/abstract-text/20371662/pubmed\" id=\"20371662\" target=\"_blank\">",
"        20371662",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Wells SA Jr, Gosnell JE, Gagel RF, et al, &ldquo;Vandetanib for the Treatment of Patients With Locally Advanced or Metastatic Hereditary Medullary Thyroid Cancer,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2010, 28(5):767-72.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?16/42/17063/abstract-text/20065189/pubmed\" id=\"20065189\" target=\"_blank\">",
"        20065189",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Wells SA, Robinson BG, Gagel RF, et al, &ldquo;Vandetanib (VAN) in Locally Advanced or Metastatic Medullary Thyroid Cancer (MTC): A Randomized, Double-Blind Phase III Trial (ZETA),&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2010, 28(15s):5503 [abstract 5503 from 2010 ASCO Annual Meeting].",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 16484 Version 29.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-122.72.76.133-F9050627AA-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f16_42_17063=[""].join("\n");
var outline_f16_42_17063=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12745724\">",
"      ALERT: U.S. Boxed Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13034485\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13812981\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12731673\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12746079\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12746080\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12746081\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12746082\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12746096\">",
"      Dosing: Adjustment for Toxicity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12747281\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12745731\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12745729\">",
"      Prescribing and Access Restrictions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12745725\">",
"      Medication Guide",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12747206\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12731675\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12731671\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12746025\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12745737\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12745738\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13300206\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12770227\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12746057\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12745733\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12745734\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12745735\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12745736\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12747205\">",
"      Dietary Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16322896\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12747267\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14721649\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12746060\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12746062\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/16484\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/16484|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?10/52/11078?source=related_link\">",
"      Vandetanib: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f16_42_17064="Invasive cervical cancer: Patterns of recurrence and posttreatment surveillance";
var content_f16_42_17064=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Invasive cervical cancer: Patterns of recurrence and posttreatment surveillance",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?16/42/17064/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?16/42/17064/contributors\">",
"     Jennifer F De Los Santos, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?16/42/17064/contributors\">",
"     J Michael Straughn, Jr, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?16/42/17064/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?16/42/17064/contributors\">",
"     Barbara Goff, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?16/42/17064/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?16/42/17064/contributors\">",
"     Don S Dizon, MD, FACP",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?16/42/17064/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Apr 9, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Despite screening programs that have dramatically reduced the incidence of cervical cancer, approximately 12,710 American women are diagnosed with this disease annually, and 4290 die from it [",
"    <a class=\"abstract\" href=\"UTD.htm?16/42/17064/abstract/1\">",
"     1",
"    </a>",
"    ]. Worldwide, cervical cancer is the second most common cancer resulting in approximately 275,000 deaths yearly [",
"    <a class=\"abstract\" href=\"UTD.htm?16/42/17064/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Squamous cell carcinoma (SCC) accounts for approximately 80 percent of cervical cancers, while adenocarcinoma accounts for 15 percent, and adenosquamous carcinoma for 3 to 5 percent; neuroendocrine or small cell carcinomas infrequently originate in the cervix. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/55/28537?source=see_link\">",
"     \"Invasive cervical cancer: Epidemiology, risk factors, clinical manifestations, and diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Management and outcomes for women with nonmetastatic invasive cervical cancer depend upon the International Federation of Gynecology and Obstetrics (FIGO) stage of disease at diagnosis (",
"    <a class=\"graphic graphic_table graphicRef79282 \" href=\"UTD.htm?33/6/33902\">",
"     table 1",
"    </a>",
"    ). In general, primary treatment for non-small cell cervical cancer (surgery or radiotherapy with or without chemotherapy) has a cure rate of approximately 80 to 95 percent in early stage disease (stage I and nonbulky stage II disease) and approximately 40 to 60 percent for bulky stage II and stage III disease. A summary of survival rates by stage of disease according to the latest FIGO data is presented in the following table (",
"    <a class=\"graphic graphic_table graphicRef64747 \" href=\"UTD.htm?27/28/28108\">",
"     table 2",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?16/42/17064/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Posttreatment surveillance after primary curative therapy for cervical cancer is uniformly recommended, although its effectiveness is not well studied. The main goal of surveillance is early detection of those recurrences that might be amenable to potentially curative salvage therapy. This is most likely with isolated central pelvic recurrences.",
"   </p>",
"   <p>",
"    The timing and location of recurrent disease following potentially curative treatment for cervical cancer, the published data on the effectiveness of various surveillance strategies, and current recommendations for posttreatment surveillance are reviewed here. Staging and primary management of invasive cervical cancer are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/14/9449?source=see_link\">",
"     \"Management of early stage cervical cancer\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/50/7976?source=see_link\">",
"     \"Management of locally advanced cervical cancer\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/21/21849?source=see_link\">",
"     \"Invasive cervical cancer: Staging and evaluation of lymph nodes\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/49/6938?source=see_link\">",
"     \"Invasive cervical adenocarcinoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     DISEASE RECURRENCE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Primary treatment for clinical stage I cervical cancer involves radical hysterectomy with bilateral pelvic and para-aortic node dissection or pelvic radiation therapy (RT) with concomitant cisplatin-based chemotherapy. Among the factors that are associated with a greater risk of disease recurrence are: larger tumor size and deep stromal invasion, invasion of the lymphovascular space, parametrial extension, histology (particularly the small cell variant), lymph node involvement, and positive resection margins.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Patterns of recurrence",
"    </span>",
"    &nbsp;&mdash;&nbsp;After either radical hysterectomy or radiation therapy for early stage disease, the predominant site of disease recurrences is local (ie, at the vaginal apex) or regional (ie, pelvic sidewall). The risk of persistent or recurrent pelvic disease increases with more advanced initial disease stage (",
"    <a class=\"graphic graphic_table graphicRef79282 \" href=\"UTD.htm?33/6/33902\">",
"     table 1",
"    </a>",
"    ). As an example, one series reported pelvic failure rates of 10, 17, 23, 42, and 74 percent among 322 women undergoing RT alone for stage IB, IIA, IIB, III, and IVA disease, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?16/42/17064/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Retrospective studies have reported the following distribution of anatomic sites of recurrence [",
"    <a class=\"abstract\" href=\"UTD.htm?16/42/17064/abstract/5-8\">",
"     5-8",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Central (ie, vaginal apex or pelvis without side wall involvement) &ndash; 22 to 56 percent",
"     </li>",
"     <li>",
"      Pelvic sidewall &ndash; 28 to 37 percent",
"     </li>",
"     <li>",
"      Distant metastases or multiple recurrence sites &ndash; 15 to 61 percent",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Patients with positive nodes at primary diagnosis have a much higher risk of distant metastases than do those with negative lymph nodes [",
"    <a class=\"abstract\" href=\"UTD.htm?16/42/17064/abstract/9\">",
"     9",
"    </a>",
"    ]. The risk of distant metastases also correlates with initial disease stage. In a series of 1211 women undergoing RT alone for cervical cancer, the 10-year actuarial incidence rates of distant metastatic disease were 3, 16, 31, 26, 39, and 75 percent for those with stage IA, IB, IIA, IIB, III, and IVA disease, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?16/42/17064/abstract/10\">",
"     10",
"    </a>",
"    ]. The location and frequency of distant metastases were:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Lung &ndash; 21 percent",
"     </li>",
"     <li>",
"      Bone &ndash;16 percent",
"     </li>",
"     <li>",
"      Paraaortic nodes &ndash;11 percent",
"     </li>",
"     <li>",
"      Abdominal cavity &ndash; 8 percent",
"     </li>",
"     <li>",
"      Supraclavicular nodes &ndash; 7 percent",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Effect of mode of treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Adjuvant RT, often with concomitant chemotherapy, is often recommended for patients who are at high risk for recurrence following radical hysterectomy. Primary treatment for patients with stage II to IV disease is cisplatin-based chemoradiotherapy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/14/9449?source=see_link\">",
"     \"Management of early stage cervical cancer\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/50/7976?source=see_link\">",
"     \"Management of locally advanced cervical cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Among patients treated for early stage disease (",
"    <a class=\"graphic graphic_table graphicRef79282 \" href=\"UTD.htm?33/6/33902\">",
"     table 1",
"    </a>",
"    ), there appears to be no difference in either the rate or anatomic distribution of recurrences in surgically treated versus irradiated patients [",
"    <a class=\"abstract\" href=\"UTD.htm?16/42/17064/abstract/5-8,11-14\">",
"     5-8,11-14",
"    </a>",
"    ]. This was best illustrated in a randomized trial of radical surgery versus RT for stage IB to IIA cervical cancer that found that there was no significance difference in the five-year survival rate or patterns of recurrence in patients who receive pelvic irradiation versus surgery alone [",
"    <a class=\"abstract\" href=\"UTD.htm?16/42/17064/abstract/11\">",
"     11",
"    </a>",
"    ]. In addition, retrospective reports of patients receiving RT alone or in conjunction with surgery show similar distributions of site of recurrence as reports of patient treated with surgery alone.",
"   </p>",
"   <p>",
"    There are no trials that directly compare surgery alone versus chemoradiotherapy, which is now preferred over RT alone because of superior survival outcomes. However, women who receive chemoradiotherapy as compared to RT alone have a significantly lower risk of locoregional relapse (18 versus 34 percent at five years in one trial [",
"    <a class=\"abstract\" href=\"UTD.htm?16/42/17064/abstract/15\">",
"     15",
"    </a>",
"    ]) as well as distant failure. Whether this would translate to a lower risk of locoregional failures with chemoradiotherapy compared to surgery alone is unknown. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/50/7976?source=see_link&amp;anchor=H3#H3\">",
"     \"Management of locally advanced cervical cancer\", section on 'Primary chemoradiation'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/14/9449?source=see_link&amp;anchor=H618915770#H618915770\">",
"     \"Management of early stage cervical cancer\", section on 'Primary radiation therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Symptomatology and timing",
"    </span>",
"    &nbsp;&mdash;&nbsp;The majority of locoregional and distant recurrences (75 percent in one review [",
"    <a class=\"abstract\" href=\"UTD.htm?16/42/17064/abstract/16\">",
"     16",
"    </a>",
"    ]) are symptomatic [",
"    <a class=\"abstract\" href=\"UTD.htm?16/42/17064/abstract/16\">",
"     16",
"    </a>",
"    ]. The median time to recurrence ranges from 7 to 36 months after primary treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?16/42/17064/abstract/7-9,12,17-22\">",
"     7-9,12,17-22",
"    </a>",
"    ]. In a systematic review of the literature, 62 to 89 percent of cervical cancer recurrences were detected within two years of primary treatment, while by year 5, 89 to 99 percent of recurrent disease had been detected.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Prognosis in recurrent disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Prognosis in recurrent disease depends upon the site of recurrence and the ability to pursue potentially curative therapy, in addition to other factors. Favorable prognostic factors include a localized, central pelvic recurrence with no side wall fixation, a disease-free interval greater than six months, and size of the recurrence less than 3 cm in diameter. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/37/33368?source=see_link\">",
"     \"Management of recurrent or metastatic cervical cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    More than 90 percent of patients who develop a distant recurrence will die of their disease within five years [",
"    <a class=\"abstract\" href=\"UTD.htm?16/42/17064/abstract/23\">",
"     23",
"    </a>",
"    ]. However, a subset of patients with isolated pulmonary metastases might be eligible for a potentially curative resection. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/37/33368?source=see_link\">",
"     \"Management of recurrent or metastatic cervical cancer\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/15/13560?source=see_link\">",
"     \"Surgical resection of pulmonary metastases: Outcomes by histology\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     SURVEILLANCE STRATEGIES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Surveillance after primary curative therapy for cervical cancer is uniformly recommended, although its effectiveness is not well studied [",
"    <a class=\"abstract\" href=\"UTD.htm?16/42/17064/abstract/16,24,25\">",
"     16,24,25",
"    </a>",
"    ]. The concept of long-term surveillance for patients treated with curative intent is based on the premise that early detection of recurrence may lead to treatments that have lower morbidity and increase survival. Early detection of recurrence is aimed at treating patients with potentially curative salvage therapy. This is most likely in women who develop a central recurrence (ie, vaginal apex or pelvis without side wall involvement), although cure of patients with isolated pulmonary metastases is also possible. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/15/13560?source=see_link\">",
"     \"Surgical resection of pulmonary metastases: Outcomes by histology\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/37/33368?source=see_link&amp;anchor=H104508737#H104508737\">",
"     \"Management of recurrent or metastatic cervical cancer\", section on 'Limited metastatic disease'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Benefit of surveillance",
"    </span>",
"    &nbsp;&mdash;&nbsp;No prospective comparative studies have specifically addressed the efficacy of routine surveillance for asymptomatic women compared to symptom-based reassessment. Retrospective series suggest that early detection of a localized disease recurrence in asymptomatic women may provide a survival benefit, but the best way to identify these women is unclear [",
"    <a class=\"abstract\" href=\"UTD.htm?16/42/17064/abstract/12,13,17,26\">",
"     12,13,17,26",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    One of these retrospective reports was an outcomes analysis of 1096 women with stage 1B cervical cancer; approximately half of the women were treated with primary surgery and the other women with primary RT alone [",
"    <a class=\"abstract\" href=\"UTD.htm?16/42/17064/abstract/17\">",
"     17",
"    </a>",
"    ]. The posttreatment surveillance strategy included physical and pelvic examination with cervicovaginal cytology every three months for one year, every four months during years 2 and 3, and every six months during years 4 and 5. A chest radiograph was performed at the end of year 1.",
"   </p>",
"   <p>",
"    Of the 133 women who recurred, only 19 were asymptomatic when diagnosed. All asymptomatic pelvic recurrences were diagnosed by pelvic examination, and routine cervical cytology smears did not detect a single case. The median survival from initial diagnosis was significantly longer among women diagnosed while asymptomatic (83 versus 31 months, respectively). Furthermore, the site of recurrence also influenced survival: patients with central pelvic and pulmonary recurrences lived significantly longer than did those with recurrences in other locations.",
"   </p>",
"   <p>",
"    Although retrospective in nature, these data provide support for routine surveillance to detect recurrences at a time when they are still asymptomatic.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Efficacy of surveillance strategies",
"    </span>",
"    &nbsp;&mdash;&nbsp;The available modalities for posttreatment surveillance include history and physical examination, including pelvic examination, vaginal vault cytology (Pap smear), chest radiograph, compute tomography (CT) scans, pelvic ultrasound, intravenous pyelography, magnetic resonance imaging (MRI), positron emission tomography (PET) scans, and circulating tumor markers. The evidence to support various methods for early detection of recurrent cervical cancer was the subject of a systematic review of 17 retrospective studies conducted by Cancer Care Ontario [",
"    <a class=\"abstract\" href=\"UTD.htm?16/42/17064/abstract/16\">",
"     16",
"    </a>",
"    ]. The findings of the review are summarized in the following sections.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Timing of follow-up visits",
"    </span>",
"    &nbsp;&mdash;&nbsp;The Cancer Care Ontario systematic review found that most patients were seen for follow-up visits every three to four months for the first two years after treatment, then every six months for the next three years, and annually thereafter [",
"    <a class=\"abstract\" href=\"UTD.htm?16/42/17064/abstract/16\">",
"     16",
"    </a>",
"    ]. There was no discernible pattern for the optimal number of follow-up visits on either detection of recurrent disease, or survival outcomes.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     History and physical examination",
"    </span>",
"    &nbsp;&mdash;&nbsp;The Cancer Care Ontario systematic review found that physical examination (including pelvic, chest and abdominal examination and careful lymph node survey) detected a median of 52 percent (range 0 to 71 percent) of asymptomatic recurrences [",
"    <a class=\"abstract\" href=\"UTD.htm?16/42/17064/abstract/16\">",
"     16",
"    </a>",
"    ]. Symptoms that raise concern for a cervical cancer recurrence include: vaginal bleeding or discharge, abdominopelvic pain, urinary symptoms,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    change in bowel habits.",
"   </p>",
"   <p>",
"    Physical examination findings suspicious for recurrence include: enlarged lymph nodes, in particular groin or supraclavicular nodes; a vaginal lesion that is friable, raised, or nodular; nodularity in the rectovaginal septum; or a palpable mass at any location, most commonly in the pelvis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Cervicovaginal cytology",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although some guidelines suggest cervicovaginal cytology at each follow-up visit [",
"    <a class=\"abstract\" href=\"UTD.htm?16/42/17064/abstract/24\">",
"     24",
"    </a>",
"    ], detection rates among asymptomatic women are low. In the Cancer Care Ontario systematic review, a median of 6 percent (range 0 to 16 percent) of asymptomatic recurrences were diagnosed based upon vaginal vault cytology [",
"    <a class=\"abstract\" href=\"UTD.htm?16/42/17064/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    It is possible that in irradiated patients, the accuracy of cervicovaginal cytology may be compromised by anatomic and tissue changes from RT. Given the limited role of cytologic evaluation in patients who have undergone pelvic radiation, elimination of cervicovaginal cytology from the posttreatment surveillance strategy was considered acceptable in guidelines from the Society of Gynecologic Oncologists. (See",
"    <a class=\"local\" href=\"#H19976081\">",
"     'Society of Gynecologic Oncology'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Chest radiograph",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the systematic review, chest radiograph detected an asymptomatic recurrence in 20 to 47 percent of cases [",
"    <a class=\"abstract\" href=\"UTD.htm?16/42/17064/abstract/16\">",
"     16",
"    </a>",
"    ]. For the small number of women who develop an isolated pulmonary recurrence, early detection might increase the proportion who are considered candidates for potentially curative metastasectomy. However, data on this subset of women were not reported in the individual studies, and there are no data to address whether early detection and treatment of these patients increased their cure rate. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/15/13560?source=see_link\">",
"     \"Surgical resection of pulmonary metastases: Outcomes by histology\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    While the period of greatest risk for disease recurrence is in the first two years, the greatest impact on survival is associated with the detection and resection of isolated pulmonary metastases after a long disease-free interval (eg, after two years).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     CT scan",
"    </span>",
"    &nbsp;&mdash;&nbsp;In most cases, CT has been used to evaluate suspected recurrence in symptomatic patients. The utility of CT as a method to detect asymptomatic recurrences has not been established, and there is no consensus on this issue. In the systematic review, between 0 and 34 percent of asymptomatic recurrences were diagnosed by CT [",
"    <a class=\"abstract\" href=\"UTD.htm?16/42/17064/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Since lymph node recurrences are likely to be asymptomatic, we follow women who had positive lymph nodes at initial surgery with",
"    <span class=\"nowrap\">",
"     abdominal/pelvic",
"    </span>",
"    CT every six months for the first two years and then annually for the next three years. In addition, we follow these women with chest CT annually for five years.",
"   </p>",
"   <p>",
"    When planning the posttreatment surveillance strategy, care should be taken to limit the number of CT scans, particularly in younger individuals, given concerns about radiation exposure and the risk for second malignancies. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/17/21785?source=see_link\">",
"     \"Radiation-related risks of imaging studies\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     SCC antigen",
"    </span>",
"    &nbsp;&mdash;&nbsp;Elevated levels of the serum tumor marker squamous cell cancer (SCC) antigen can precede clinical detection of recurrence by 4 to 16 months [",
"    <a class=\"abstract\" href=\"UTD.htm?16/42/17064/abstract/18,27-30\">",
"     18,27-30",
"    </a>",
"    ]. However, the value of serial assays of SCC antigen for posttreatment surveillance has not been established. In a review of 225 patients, SCC antigen was insensitive for the detection of early recurrence, and survival was no better among women whose disease recurrence was diagnosed by elevations in SCC antigen compared to those diagnosed by other means [",
"    <a class=\"abstract\" href=\"UTD.htm?16/42/17064/abstract/18\">",
"     18",
"    </a>",
"    ]. Furthermore, the false-positive rate was 12 percent when using elevated levels as a marker of cervical cancer recurrence. The utility of SCC antigen was not addressed in the Cancer Care Ontario systematic review [",
"    <a class=\"abstract\" href=\"UTD.htm?16/42/17064/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Until further information becomes available, the routine use of SCC antigen as a component of the posttreatment surveillance strategy cannot be recommended.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     PET scan",
"    </span>",
"    &nbsp;&mdash;&nbsp;Initial staging of cervical cancer is a Medicare-reimbursable indication for PET scanning. FDG-PET is a sensitive and specific method of detecting lymph node metastases in newly diagnosed cervical cancer, and most institutions perform a PET scan during initial staging as an adjunct to conventional imaging. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/21/21849?source=see_link\">",
"     \"Invasive cervical cancer: Staging and evaluation of lymph nodes\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The value of PET as a component of routine posttreatment surveillance has not been systematically studied, and it was not addressed by the studies in the Cancer Care Ontario systematic review [",
"    <a class=\"abstract\" href=\"UTD.htm?16/42/17064/abstract/16\">",
"     16",
"    </a>",
"    ]. There are conflicting data regarding the utility of this modality [",
"    <a class=\"abstract\" href=\"UTD.htm?16/42/17064/abstract/31-35\">",
"     31-35",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a prospective registry study of 103 patients treated with definitive chemoradiation for advanced cervical cancer who demonstrated no abnormal FDG uptake on their three-month posttherapy FDG-PET, those who had an asymptomatic recurrence detected by PET had a higher three-year cause-specific survival than those who were symptomatic at the time of disease recurrence (59 versus 19 percent) [",
"      <a class=\"abstract\" href=\"UTD.htm?16/42/17064/abstract/32\">",
"       32",
"      </a>",
"      ]. While it is possible that symptomatic patients have worse biologic disease, these findings suggest that earlier discovery by more sensitive imaging may potentially translate into improved outcomes. &nbsp;",
"     </li>",
"     <li>",
"      The limitations of using PET for posttreatment cervical cancer surveillance were noted in a report of 121 women who had undergone whole body PET at least six months after successfully completing treatment for primary cervical cancer; 76 were diagnosed with a recurrence, 20 of whom were asymptomatic at the time of diagnosis [",
"      <a class=\"abstract\" href=\"UTD.htm?16/42/17064/abstract/31\">",
"       31",
"      </a>",
"      ]. PET scan was performed for a variety of reasons (tumor marker elevation, abnormal physical examination or imaging study, or abnormal histology on smear); 30 women received the test for no reason other than as a component of routine posttreatment surveillance.",
"      <br/>",
"      <br/>",
"      Although PET detected disease in 17 of 20 asymptomatic patients with recurrence (85 percent sensitivity), all had undergone the PET for workup of an abnormal finding. Six of the 30 patients who underwent a PET scan as a component of routine surveillance had a positive PET; all six were determined to be false positive studies.",
"     </li>",
"     <li>",
"      Other investigators suggest utility for a posttreatment PET scan in prognostic stratification among patients treated with a nonsurgical approach [",
"      <a class=\"abstract\" href=\"UTD.htm?16/42/17064/abstract/35,36\">",
"       35,36",
"      </a>",
"      ]. In the larger of the two series, 105 patients treated with concurrent chemoradiotherapy underwent a posttreatment PET between 3 and 12 months (median 4.6) after treatment completion [",
"      <a class=\"abstract\" href=\"UTD.htm?16/42/17064/abstract/36\">",
"       36",
"      </a>",
"      ]. A complete metabolic response (no FDG uptake) was noted in 73 (70 percent). The presence of a complete metabolic response was a powerful predictor of survival (three-year cause-specific survival 98 percent, compared with 40 percent in those without a complete metabolic response).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These data suggest that PET is useful in the diagnostic workup of abnormal findings on physical examination, but that further study is needed to prove value from including PET in the routine posttreatment surveillance strategy for asymptomatic patients. Posttreatment PET scanning is not recommended as a surveillance strategy by any expert group. (See",
"    <a class=\"local\" href=\"#H18\">",
"     'Recommendations of expert groups'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    The role of PET in women with a suspected recurrence of cervical cancer is discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/37/33368?source=see_link&amp;anchor=H172229098#H172229098\">",
"     \"Management of recurrent or metastatic cervical cancer\", section on 'Diagnostic evaluation'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     Other tests",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the systematic review, all other studies, including ultrasound, MRI, and intravenous pyelogram (IVP) were not of clinical benefit in detecting recurrent disease [",
"    <a class=\"abstract\" href=\"UTD.htm?16/42/17064/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     RECOMMENDATIONS OF EXPERT GROUPS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The optimal surveillance strategy has not been established, and clinical practice is variable. Guidelines are available from several expert groups.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Cancer Care Ontario",
"    </span>",
"    &nbsp;&mdash;&nbsp;An analysis of the available evidence by the Cancer Care Ontario's Program in Evidence-based Care concluded that there was at best only modest low quality evidence to inform the most appropriate follow-up strategy for patients with cervical cancer who are disease-free after receiving primary treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?16/42/17064/abstract/16\">",
"     16",
"    </a>",
"    ]. This is particularly true for patients with locally advanced disease as most of the available data include a majority of patients treated for early stage disease.",
"   </p>",
"   <p>",
"    They suggested the following broad features of a posttreatment surveillance strategy:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Periodic follow-up visits to include history and complete physical examination, including vaginal vault inspection and bimanual pelvic examination. The optimal frequency is not established, as there are no comparative data to assess whether the number of follow-up visits impacts on patient outcomes. Most studies followed similar intervals with approximately 12 to 15 visits over a five-year period.",
"     </li>",
"     <li>",
"      Vaginal vault cytology annually",
"     </li>",
"     <li>",
"      The routine use of various other radiologic or biologic follow-up investigations in asymptomatic patients was not advocated.",
"     </li>",
"     <li>",
"      Patients should return to annual population-based general screening after five years of recurrence-free follow-up, as the majority of recurrences occur within this time frame.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     National Comprehensive Cancer Network",
"    </span>",
"    &nbsp;&mdash;&nbsp;Consensus-based guidelines from the National Comprehensive Cancer Network (NCCN) suggest the following [",
"    <a class=\"abstract\" href=\"UTD.htm?16/42/17064/abstract/24\">",
"     24",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Clinical evaluation every three to six months for two years, every six months during years 3 to 5, and then annually. Clinical evaluation consists of a review of systems and physical examination with particular attention to the supraclavicular and inguinal lymph nodes, as well as rectovaginal and abdominal examinations, and cervicovaginal cytology.",
"     </li>",
"     <li>",
"      Annual chest x-ray (optional)",
"     </li>",
"     <li>",
"      Other radiographic studies, including CT or PET scan, only as clinically indicated",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     American Congress of Obstetricians and Gynecologists",
"    </span>",
"    &nbsp;&mdash;&nbsp;Year 2002 guidelines for diagnosis and treatment of cervical cancer from the American Congress of Obstetricians and Gynecologists (ACOG) make the following recommendations for posttreatment surveillance [",
"    <a class=\"abstract\" href=\"UTD.htm?16/42/17064/abstract/25\">",
"     25",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Follow-up examinations every four months for the first two years, and every six months during years 3 to 5.",
"     </li>",
"     <li>",
"      Annual Pap smear",
"     </li>",
"     <li>",
"      Annual chest x-ray for up to five years",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19976081\">",
"    <span class=\"h2\">",
"     Society of Gynecologic Oncology",
"    </span>",
"    &nbsp;&mdash;&nbsp;Consensus-based guidelines for posttreatment surveillance of cervical cancer are available from the Society of Gynecologic Oncologists and include the following [",
"    <a class=\"abstract\" href=\"UTD.htm?16/42/17064/abstract/37\">",
"     37",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Physical examination and review of symptoms:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      For high-risk disease (advanced stage, treated with primary",
"      <span class=\"nowrap\">",
"       chemotherapy/radiation",
"      </span>",
"      therapy or surgery plus adjuvant therapy), every three months for the first two years, every six months for years 3 and 5, and then annually.",
"     </li>",
"     <li>",
"      For low-risk disease (early stage, treated with surgery alone, no adjuvant therapy), every six months for the first two years, then annually.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Pap test yearly for all patients. However, the role of cytologic evaluation in patients who have undergone pelvic RT is limited, and the panel concluded that elimination of its use in routine surveillance may be acceptable.",
"     </li>",
"     <li>",
"      Insufficient data to support routine use of radiographic imaging (chest x-ray, positron emission",
"      <span class=\"nowrap\">",
"       tomography(PET)/computed",
"      </span>",
"      tomography (CT), magnetic resonance imaging).",
"     </li>",
"     <li>",
"      CT",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      PET only if recurrence suspected.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The guidelines did not address the use of SCC antigen or other tumor markers.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Surveillance after primary curative therapy for cervical cancer is uniformly recommended, although its effectiveness is not well studied. The main goal of surveillance is early detection of those recurrences that might be amenable to potentially curative salvage therapy. This is most likely in patients who have an isolated central pelvic recurrence. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The optimal surveillance strategy has not been established. There is consensus on the need to perform clinical evaluation (a review of systems, physical examination with particular attention to the supraclavicular and inguinal lymph nodes as well as careful rectovaginal and abdominal examinations), and cervicovaginal cytology and a chest radiography periodically following therapy, but the optimal frequency is unknown. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Efficacy of surveillance strategies'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    We follow the approach as outlined in the recommendations of the SGO (see",
"    <a class=\"local\" href=\"#H19976081\">",
"     'Society of Gynecologic Oncology'",
"    </a>",
"    above):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Careful clinical evaluation is the most important component of the follow-up for patients with cervical cancer (a review of systems and physical examination with particular attention to the supraclavicular and inguinal lymph nodes, as well as rectovaginal and abdominal examinations). (See",
"      <a class=\"local\" href=\"#H11\">",
"       'History and physical examination'",
"      </a>",
"      above.)",
"      <br/>",
"      <br/>",
"      We perform evaluations on the following schedule depending on disease extent:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      For high-risk disease (advanced stage, treated with primary",
"      <span class=\"nowrap\">",
"       chemotherapy/radiation",
"      </span>",
"      therapy or surgery plus adjuvant therapy), every three months for the first two years, every six months for years 3 and 5, and then annually.",
"     </li>",
"     <li>",
"      For low-risk disease (early stage, treated with surgery alone, no adjuvant therapy), every six months for the first two years, then annually.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      We suggest annual cervicovaginal cytology rather than at every follow-up visit for all patients except for those who have undergone pelvic RT, in whom we eliminate cytologic examination as a component of posttreatment surveillance (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Cervicovaginal cytology'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    We suggest not pursuing surveillance radiographic imaging (chest x-ray, positron emission tomography",
"    <span class=\"nowrap\">",
"     (PET)/computed",
"    </span>",
"    tomography (CT), magnetic resonance imaging) unless a recurrence is suspected (",
"    <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"     Grade 2C",
"    </a>",
"    ). (See",
"    <a class=\"local\" href=\"#H14\">",
"     'CT scan'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H16\">",
"     'PET scan'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      We suggest not using assays of SCC antigen, PET scans, pelvic ultrasound, intravenous pyelography (IVP), or MRI as a routine component of the posttreatment surveillance strategy in asymptomatic patients (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H15\">",
"       'SCC antigen'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H16\">",
"       'PET scan'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H17\">",
"       'Other tests'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/42/17064/abstract/1\">",
"      Siegel R, Ward E, Brawley O, Jemal A. Cancer statistics, 2011: The impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA Cancer J Clin 2011; 61:212.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/42/17064/abstract/2\">",
"      Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 2005; 55:74.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/42/17064/abstract/3\">",
"      Quinn MA, Benedet JL, Odicino F, et al. Carcinoma of the cervix uteri. FIGO 26th Annual Report on the Results of Treatment in Gynecological Cancer. Int J Gynaecol Obstet 2006; 95 Suppl 1:S43.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/42/17064/abstract/4\">",
"      Perez CA, Grigsby PW, Camel HM, et al. Irradiation alone or combined with surgery in stage IB, IIA, and IIB carcinoma of uterine cervix: update of a nonrandomized comparison. Int J Radiat Oncol Biol Phys 1995; 31:703.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/42/17064/abstract/5\">",
"      Muram D, Curry RH, Drouin P. Cytologic follow-up of patients with invasive cervical carcinoma treated by radiotherapy. Am J Obstet Gynecol 1982; 142:350.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/42/17064/abstract/6\">",
"      Rintala MA, Rantanen VT, Salmi TA, et al. PAP smear after radiation therapy for cervical carcinoma. Anticancer Res 1997; 17:3747.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/42/17064/abstract/7\">",
"      Gerdin E, Cnattingius S, Johnson P, Pettersson B. Prognostic factors and relapse patterns in early-stage cervical carcinoma after brachytherapy and radical hysterectomy. Gynecol Oncol 1994; 53:314.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/42/17064/abstract/8\">",
"      Morice P, Deyrolle C, Rey A, et al. Value of routine follow-up procedures for patients with stage I/II cervical cancer treated with combined surgery-radiation therapy. Ann Oncol 2004; 15:218.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/42/17064/abstract/9\">",
"      Sartori E, Pasinetti B, Carrara L, et al. Pattern of failure and value of follow-up procedures in endometrial and cervical cancer patients. Gynecol Oncol 2007; 107:S241.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/42/17064/abstract/10\">",
"      Fagundes H, Perez CA, Grigsby PW, Lockett MA. Distant metastases after irradiation alone in carcinoma of the uterine cervix. Int J Radiat Oncol Biol Phys 1992; 24:197.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/42/17064/abstract/11\">",
"      Landoni F, Maneo A, Colombo A, et al. Randomised study of radical surgery versus radiotherapy for stage Ib-IIa cervical cancer. Lancet 1997; 350:535.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/42/17064/abstract/12\">",
"      Samlal RA, Van Der Velden J, Van Eerden T, et al. Recurrent cervical carcinoma after radical hysterectomy: an analysis of clinical aspects and prognosis. Int J Gynecol Cancer 1998; 8:78.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/42/17064/abstract/13\">",
"      Larson DM, Copeland LJ, Stringer CA, et al. Recurrent cervical carcinoma after radical hysterectomy. Gynecol Oncol 1988; 30:381.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/42/17064/abstract/14\">",
"      Krebs HB, Helmkamp BF, Sevin BU, et al. Recurrent cancer of the cervix following radical hysterectomy and pelvic node dissection. Obstet Gynecol 1982; 59:422.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/42/17064/abstract/15\">",
"      Eifel PJ, Winter K, Morris M, et al. Pelvic irradiation with concurrent chemotherapy versus pelvic and para-aortic irradiation for high-risk cervical cancer: an update of radiation therapy oncology group trial (RTOG) 90-01. J Clin Oncol 2004; 22:872.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/42/17064/abstract/16\">",
"      Elit L, Fyles AW, Devries MC, et al. Follow-up for women after treatment for cervical cancer: a systematic review. Gynecol Oncol 2009; 114:528.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/42/17064/abstract/17\">",
"      Bodurka-Bevers D, Morris M, Eifel PJ, et al. Posttherapy surveillance of women with cervical cancer: an outcomes analysis. Gynecol Oncol 2000; 78:187.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/42/17064/abstract/18\">",
"      Esajas MD, Duk JM, de Bruijn HW, et al. Clinical value of routine serum squamous cell carcinoma antigen in follow-up of patients with early-stage cervical cancer. J Clin Oncol 2001; 19:3960.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/42/17064/abstract/19\">",
"      Ansink A, de Barros Lopes A, Naik R, Monaghan JM. Recurrent stage IB cervical carcinoma: evaluation of the effectiveness of routine follow up surveillance. Br J Obstet Gynaecol 1996; 103:1156.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/42/17064/abstract/20\">",
"      Duyn A, Van Eijkeren M, Kenter G, et al. Recurrent cervical cancer: detection and prognosis. Acta Obstet Gynecol Scand 2002; 81:759.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/42/17064/abstract/21\">",
"      Beadle BM, Jhingran A, Yom SS, et al. Patterns of regional recurrence after definitive radiotherapy for cervical cancer. Int J Radiat Oncol Biol Phys 2010; 76:1396.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/42/17064/abstract/22\">",
"      Soisson AP, Geszler G, Soper JT, et al. A comparison of symptomatology, physical examination, and vaginal cytology in the detection of recurrent cervical carcinoma after radical hysterectomy. Obstet Gynecol 1990; 76:106.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/42/17064/abstract/23\">",
"      Hong JH, Tsai CS, Lai CH, et al. Recurrent squamous cell carcinoma of cervix after definitive radiotherapy. Int J Radiat Oncol Biol Phys 2004; 60:249.",
"     </a>",
"    </li>",
"    <li>",
"     National Comprehensive Cancer Network (NCCN) guidelines. Available at: www.nccn.org (Accessed on May 15, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/42/17064/abstract/25\">",
"      American College of Obstetricians and Gynecologists.. ACOG practice bulletin. Diagnosis and treatment of cervical carcinomas. Number 35, May 2002. American College of Obstetricians and Gynecologists. Int J Gynaecol Obstet 2002; 78:79.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/42/17064/abstract/26\">",
"      Chou HH, Wang CC, Lai CH, et al. Isolated paraaortic lymph node recurrence after definitive irradiation for cervical carcinoma. Int J Radiat Oncol Biol Phys 2001; 51:442.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/42/17064/abstract/27\">",
"      Maiman M. The clinical application of serum squamous cell carcinoma antigen level monitoring in invasive cervical carcinoma. Gynecol Oncol 2002; 84:4.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/42/17064/abstract/28\">",
"      Chan YM, Ng TY, Ngan HY, Wong LC. Monitoring of serum squamous cell carcinoma antigen levels in invasive cervical cancer: is it cost-effective? Gynecol Oncol 2002; 84:7.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/42/17064/abstract/29\">",
"      Micke O, Prott FJ, Sch&auml;fer U, et al. The impact of squamous cell carcinoma (SCC) antigen in the follow-up after radiotherapy in patients with cervical cancer. Anticancer Res 2000; 20:5113.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/42/17064/abstract/30\">",
"      Chang TC, Law KS, Hong JH, et al. Positron emission tomography for unexplained elevation of serum squamous cell carcinoma antigen levels during follow-up for patients with cervical malignancies: a phase II study. Cancer 2004; 101:164.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/42/17064/abstract/31\">",
"      Chung HH, Kim SK, Kim TH, et al. Clinical impact of FDG-PET imaging in post-therapy surveillance of uterine cervical cancer: from diagnosis to prognosis. Gynecol Oncol 2006; 103:165.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/42/17064/abstract/32\">",
"      Brooks RA, Rader JS, Dehdashti F, et al. Surveillance FDG-PET detection of asymptomatic recurrences in patients with cervical cancer. Gynecol Oncol 2009; 112:104.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/42/17064/abstract/33\">",
"      Grigsby PW, Siegel BA, Dehdashti F, Mutch DG. Posttherapy surveillance monitoring of cervical cancer by FDG-PET. Int J Radiat Oncol Biol Phys 2003; 55:907.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/42/17064/abstract/34\">",
"      Ryu SY, Kim MH, Choi SC, et al. Detection of early recurrence with 18F-FDG PET in patients with cervical cancer. J Nucl Med 2003; 44:347.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/42/17064/abstract/35\">",
"      Siva S, Herschtal A, Thomas JM, et al. Impact of post-therapy positron emission tomography on prognostic stratification and surveillance after chemoradiotherapy for cervical cancer. Cancer 2011; 117:3981.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/42/17064/abstract/36\">",
"      Schwarz JK, Siegel BA, Dehdashti F, Grigsby PW. Association of posttherapy positron emission tomography with tumor response and survival in cervical carcinoma. JAMA 2007; 298:2289.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/42/17064/abstract/37\">",
"      Salani R, Backes FJ, Fung MF, et al. Posttreatment surveillance and diagnosis of recurrence in women with gynecologic malignancies: Society of Gynecologic Oncologists recommendations. Am J Obstet Gynecol 2011; 204:466.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 3227 Version 12.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-202.43.93.2-77D3A94D3A-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f16_42_17064=[""].join("\n");
var outline_f16_42_17064=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H22\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      DISEASE RECURRENCE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Patterns of recurrence",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Effect of mode of treatment",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Symptomatology and timing",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Prognosis in recurrent disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      SURVEILLANCE STRATEGIES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Benefit of surveillance",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Efficacy of surveillance strategies",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Timing of follow-up visits",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - History and physical examination",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Cervicovaginal cytology",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Chest radiograph",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - CT scan",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - SCC antigen",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - PET scan",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - Other tests",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      RECOMMENDATIONS OF EXPERT GROUPS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Cancer Care Ontario",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      National Comprehensive Cancer Network",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      American Congress of Obstetricians and Gynecologists",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19976081\">",
"      Society of Gynecologic Oncology",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ONC/3227\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/3227|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?33/6/33902\" title=\"table 1\">",
"      Staging cervical cancer",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?27/28/28108\" title=\"table 2\">",
"      Cervical cancer survival",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/49/6938?source=related_link\">",
"      Invasive cervical adenocarcinoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/55/28537?source=related_link\">",
"      Invasive cervical cancer: Epidemiology, risk factors, clinical manifestations, and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/21/21849?source=related_link\">",
"      Invasive cervical cancer: Staging and evaluation of lymph nodes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/14/9449?source=related_link\">",
"      Management of early stage cervical cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/50/7976?source=related_link\">",
"      Management of locally advanced cervical cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/37/33368?source=related_link\">",
"      Management of recurrent or metastatic cervical cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/17/21785?source=related_link\">",
"      Radiation-related risks of imaging studies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/15/13560?source=related_link\">",
"      Surgical resection of pulmonary metastases: Outcomes by histology",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f16_42_17065="Anatomic distributions of the trigeminal nerve";
var content_f16_42_17065=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F52850&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F52850&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 604px\">",
"   <div class=\"ttl\">",
"    Anatomic distributions of the trigeminal nerve",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 584px; height: 578px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Kassutto Z. Orofacial anesthesia techniques. In: Textbook of Pediatric Procedures, 2nd Edition, King C, Henretig FM (Eds), Lippincott Williams &amp; Wilkins, Philadelphia, 2008. Copyright &copy; 2008 Lippincott Williams &amp; Wilkins.",
"    </div>",
"    <div class=\"contractual\">",
"     <br/>",
"     <a href=\"file://www.lww.com\">",
"      file://www.lww.com",
"     </a>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f16_42_17065=[""].join("\n");
var outline_f16_42_17065=null;
var title_f16_42_17066="Hamartoma with cartilage";
var content_f16_42_17066=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F62271%7EPULM%2F72996&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F62271%7EPULM%2F72996&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Pulmonary hamartoma",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 404px; height: 263px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Low power photomicrograph shows a predominance of cartilagenous tissue. The cleft-like space on the left of the image is lined with cuboidal respiratory epithelium.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     From Colby, TV, Koss, MN, Travis, WD. Tumors of the Lower Respiratory Tract. Armed Forces Institute of Pathology, Washington, DC.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Pulmonary hamartoma",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 414px; height: 270px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Low power photomicrograph shows a pulmonary hamartoma composed largely of fat. An elongated cleft lined by respiratory epithelium (arrow) is visible at the left.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     From Colby, TV, Koss, MN, Travis, WD. Tumors of the Lower Respiratory Tract. Armed Forces Institute of Pathology, Washington, DC.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f16_42_17066=[""].join("\n");
var outline_f16_42_17066=null;
var title_f16_42_17067="Types of low grade glioma";
var content_f16_42_17067=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F55759&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F55759&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Pathologic tumor subtypes which could be considered under the rubric of low grade glioma",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Common tumor types included",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Diffuse astrocytoma",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        - Fibrillary",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        - Protoplasmic",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        - Gemistocytic",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Pilocytic astrocytoma",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Oligodendroglioma",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Mixed oligoastrocytomas",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Potential tumor types that fit under a broader definition",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Ependymoma",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Pleomorphic xanthoastrocytoma",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Ganglioglioma",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Astroblastoma",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Subependymoma",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f16_42_17067=[""].join("\n");
var outline_f16_42_17067=null;
var title_f16_42_17068="Drug ratings in pregnancy";
var content_f16_42_17068=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DRUG%2F50021&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DRUG%2F50021&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Drug ratings in pregnancy (US Food &amp; Drug Administration)",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Category",
"       </td>",
"       <td class=\"subtitle1\">",
"        Interpretation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"centered\" rowspan=\"2\">",
"        A",
"       </td>",
"       <td class=\"sublist1_start\">",
"        Controlled human studies show no risk",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Controlled studies in pregnant women fail to demonstrate a risk to the fetus in the first trimester with no evidence of risk in later trimesters. The possibility of fetal harm appears remote.",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td class=\"centered\" rowspan=\"2\">",
"        B",
"       </td>",
"       <td class=\"sublist1_start\">",
"        No evidence of risk in studies",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Either animal-reproduction studies have not demonstrated a fetal risk but there are no controlled studies in pregnant women, or animal-reproduction studies have shown an adverse effect (other than a decrease in fertility) that was not confirmed in controlled studies in women in the first trimester and there is no evidence of a risk in later trimesters.",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td class=\"centered\" rowspan=\"2\">",
"        C",
"       </td>",
"       <td class=\"sublist1_start\">",
"        Risk cannot be ruled out",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Either studies in animals have revealed adverse effects on the fetus (teratogenic or embryocidal effects or other) and there are no controlled studies in women, or studies in women and animals are not available. Drugs should be given only if the potential benefits justify the potential risk to the fetus.",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td class=\"centered\" rowspan=\"2\">",
"        D",
"       </td>",
"       <td class=\"sublist1_start\">",
"        Positive evidence of risk",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        There is positive evidence of human fetal risk, but the benefits from use in pregnant women may be acceptable despite the risk (eg, if the drug is needed in a life-threatening situation or for a serious disease for which safer drugs cannot be used or are ineffective).",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td class=\"centered\" rowspan=\"2\">",
"        X",
"       </td>",
"       <td class=\"sublist1_start\">",
"        Contraindicated in pregnancy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Studies in animals or human beings have demonstrated fetal abnormalities or there is evidence of fetal risk based on human experience, or both, and the risk of the use of the drug in pregnant women clearly outweighs any possible benefit. The drug is contraindicated in women who are or may become pregnant.",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Lexicomp Online. Copyright &copy; 1978-2013 Lexicomp, Inc. All Rights Reserved.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f16_42_17068=[""].join("\n");
var outline_f16_42_17068=null;
var title_f16_42_17069="Amiodarone in SCD survivors";
var content_f16_42_17069=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F60700&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F60700&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 504px\">",
"   <div class=\"ttl\">",
"    Amiodarone is beneficial in survivors of sudden death",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 484px; height: 279px; background-image: url(data:image/gif;base64,R0lGODlh5AEXAeYAAP///4CAgAAAAP8AAP+AgIaG/wAz/zMzM6Wl///w8MzMzP9QUIiIiHd3dysr/6qqqu7u7lVVVfHx/xEREf+IiBFB//8QEP8REVlZ//+goP8wMP/Q0A0N/2ZmZuLi/8PD//+wsEpK/yIiIu7x/5mZmf/MzP/u7v8zM8DAwP8gIERERP93d0BAQBwc//9VVf+qqv/g4P9gYN3d3Xd3//+QkLu7u1V3/2ho/4ig/6q7/3eS//9wcP/AwP9ERDNc//9AQP8iIiJO/0Rp/8zW///d3Zmt/2aF//9mZt3k//+ZmTs7/7vJ/9LS/5aW/48QEFgpz49AQO8AD0k677S0/+GRr9ECL8+AgP+7uwAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAACH5BAAAAAAALAAAAADkARcBAAf/gACCg4SFhoeIiYqLjI2Oj5CRkpOUlZaXmJmam5ydnp+goaKjpKWmp6ipqqusra6vsLGys7S1tre4ubq7vL2+v8DBwsPExcbHyMnKy8zNzs/Q0dLT1NXW19jZ2tvc3d7f4OHi4+Tl5ufo6err7O3u7/Dx8vP09fb3+Pn6+/z9/v8AAwocSLCgwYMIEypcyLChw4cQI0qcSBFiDQERBpGYIEAAA0EKDnTMWLGkSUciMYIUcABABAEPAIiYAIGBgAYnc+o0pEAlAJs4gfZsOVQQigBIkVqhsrMpxJ4kG3j8efOByqIAjiYNACXKEwROwyqEKggo1QZFsRoK4KSKlBYF/ySInTuQLICiKmDKpGn2ENIFCz6EgCuXruF9KTsqALCx48e7KUn6DZBAAwEATG5wuOHhsGeJSAFssABCkAfNnD+rZhgaAAgLGwZ5mNECw4fVuA22BkBAQwJCEgq0CHE7t/F/uwEANiShiQMlYI9Lz5e88uVDCBw4iD69u7zkokknQqDEQZPC3tOvA+8atiLBhNXLP8eet+9FHzC0mNF5vn9w9Sm3QCOnbdbffwhmE6B1jhR4AxMJRlhNgOGV5khwwxUn4YbNUNhebI9gGMIUHJaYjIf2/RZJdtuZ6OIwKApICYvcvWijLjEyOKN2Nd7o4ywxVmgJjT8WGUuQH15CpP+RTKqCZIqYLNnklKM8KWMmUlKpJSdW6oglj1uGmYmVQm6SpZhoPkJmkpycmeabiKwJZSduwmknAHJe6Umdd6KZp5d7gtknnHmWCQqfgzZZKJuhIJroj4vOKYqjj74YqZ6jUFoph5cCmqmgm954qaGl0IheqCWOyqgpCITAAQYInIpqgqpKeooECGDwaqyz0hoAJ8uxgquusMraa3e1AuCpKsPuauyxuSVLaivNFgvtcdKu+kq1vF6rWra2xsLts942BS6mtIxbrljnLpturs6uu9O54dHAi7rylkSvaxqkQICKuuCb7z5WddQRTondFOevo/CwgAUxwNBLsyH0OHD/PiLoJVJMiuxLCAwxWLAAD77g6gBxF+tjE0mJqQCBUVsFwALDpiRAQAoaZPCLcBgcmPI8EHC0GCEdCNABzFvNvEoG/f478QwczEDuz+tIdXQhVklWiMeKOAyxxLx4oF8BVMPTE02CQKCCDAAU/dhaNLMCssgk8yJYi2WzkxdOg+TlWCJcN2Izzjrzkh3KefsT+CNM+wtwLjz7nDg+i0PidcS7SAC11JNTFzctc4+8i9hwdX5P5ZMMnvMud1tsujuoV9K407kcruHrsH+uy+Vg4xI57rkHE3rdt2ge9dTAixO7JqpbeAvpZCePzvKcZGDBDo/X0rr05lDPCQw/aAAi/y62cz+O950QMIC9uvxu/jfod7JBCgtkX4vxnL/PTfydJPAw8biAnv62wT9PWG8HdguBAwrwAckNMBoF9AQMNKCB3tUOA67iQAhuwEAHPvBEulPGDixQuF544AMFuEEGN9jBDyIjgqDggcjsZ0IUqpADGuRgA10YDBiCwn8pGF8xTpjCFerQgzwEUgibQYMBXGcZRLxhDluYRFn4UBQb0MAPLNiMKK4QVlV0xRVFkYAROm8aRDzZ7cJ4ijGO4jXYw4b72GgKN44CfOLDBv6QR8dN2JEU6mPfNQTowhqwDQCGrNISqTG/+mVjew88AN8a0BJR/LEU/rMAAK1RPvPV4P8AExDBAUBZyVBc0hQH3MYcgVcwg02ABIoExwQrqI09Sg8CHWAABF5GilOiYoQlxAYhgVeTBhjzbaDwJSpk6EhtQPJ1futIKZO5yG0AUYjY6OTkIMCSB3izBrEsRxOfqI1Vlk2SbaxmN7K4RW7YMm8dEIExG4DMTyiTFWW0AA2wOcix5S1h07SnOr8BggWkYAA/IAAIaCiNZ9KjAgYYATxq4M1vhnMdCQABAX4wgBTEYJ/X0OY0dGAAAyyBESMwQAUYAVGJwkMGD4BATC/6jg3QIAYHTehCqWHOZwShpEbYREvhYROYHOBqphyoOjK60Y5+lJ/LeOczcmAAH1SgAhL/JakQIGoEG6h0CAC4KgBGIISSBiEHYy3rVSPq1ZIKAQkprUBZR1AEiBrABmNVqVrBWoSf3jUaohTBAyhJ03vYFKcIVShDjTHMZngVB48FAElxEFYDIKEIBgiqWL2agxEEAauRHaogHpvSkhpgCFUFAA4MoIO4qvauqPUBAIxggCI8g5sPOMADOhBQT9xTGEzlqEdBuoy7FeC4yE2ucpfL3OY697nQXe4akWDaksp2spUdAVXxKtah+sAAOfguWFuKA7+y1rWv1QEAqOoD1253tdVV7zNEwNsGTACp1CTIYXOq2GQgYAbRDbCAB0xgBhZitXgFwE+XgN2WbjesK+Ws/2exWla0QhS1K11ta1UqiNim172wTe00SODKQyYVIcF1agYWu5CfolWymW1wRB8sVrJaF61I+KlV2Wrd83JYEHUFal5X+uC+mpay0KgBPU18YobYdAEDWMCK+xiKBqgAMrBkBDcNppeQjARwSh1IAjIAZSmzmMqTmMBjItDbQ2yZl4KYSU0UNpmJjLnMU0bzJXArCMJqmcs4SQtLkJYUpVXkzlHOs54nMUoSbAS/jRAJCbJ2l0FnJWaGNgmizbzoSJC4IxNgciOkwgBBtxlPYXbIphXd6UUoYMmOeADLBLAYOfcFbmJZ9ZkX3QFIM0IGGROACLLsZZ/UmS66brUh2P+czs8kW9k/mcA86+nbVOfk2YsGaGFVg+0+1oABFeVYk6Wzai4msai59XUnfjsPRGuAuEkM7GBP7UdreyajIUvBDs6oP9zqlrfbls8GdpACiLGae/SV5H0D7h8Y0EADUaaBuV/3aQGEmuEIurMFNLADqE5OyQwQtUB9BAKcepTf/3DBAF6wiAsMwASIWMEAKKAPdhtk4BoQ2cGpUYIB+NznL6DAzwfgAphHQuY0H4TKWa4IlxtdEE4HANKhQYIDqEDcGH+Rw6H87ok/o+cnIITQVwCAsWdi6S1/OSGiPnVnXMRgQ8v6jcac745PA+xiHwDZX0B0QrwACANwedhPMID/EvT8AmWfOQCO4HOXs1zoPqe5CXoQ+KgLQuU+X4HMe+ByFwDABJgHAssJv3TMD6AHRDBB4AkPBCJQnuaUL8Eq7OtoaZfC5g8BAcEhtlNn9HzoJjA745MuCMAbfgCDL/zhE08BoXt+6WYHPBFUTnPLQ13tU3d5CZZOhAEAAQCEB7rSZ656xCfh9Hw/Qfd7wApK7lKScB53mmwK8QUQ4P74z7/+98///vv//wC4f5uEd4MAeZFHCMuHd4R3fIgndBQwdaU3dCu3gABgfRWIfYq3gC4HfBRYdoCXeeUHAHgHeGg3e1wmTXKnJTCQAQHYgi74gjB4fwOIfHlHdodwARdg/wJXQIOE9wLL54BmR3lBNwBHQAhCeIFPd4FEIHUZWHgqlwSEQIE/qHch6HyJ532tIBUnSG+agHvy8ns/N4Q2aAhJIHg0yHenF3jMBwCUdwE9eIU+VwJEAHgnYIGQp3lNWAKg93OI14GYR3grUH4u1wMwZwIuR3yrsEuKGH/5BW2tIHRFCAwhSAiGiHjY4IXSI3M+R4jBMIkFqHcKYm+OWCSYOIoRUYqm+BComIoNsYqsuBCu+IoJEYuyeBC0WIsFcYu4OBC6uIsB0Yu+iByiGIwRAozEyA/GeIw1N4zK6B/J2Iynw4zQqB7POI30UI3W+B3SmI3TgY3c+A7e+I3tEP+O4mgNL/E3AJAwfINr5YgbEcA2IgFOG7MI5NiO1jCPLcNLWlFo22iPE5EXIlAIRXM1+4gUmeaPh6EAGTMBcScIlHZsCGkYPcESQ6M2bOM2CxORCXmCGRFN1DYI9aiRytOPIjkXIVmS8EOSKOkUJ7mS+6OSLqkTLRmToUiT1AiTNqkvOJmTFDGTPEkNPvmT0hCUQgkNRFmUznCUSMkMSrmUytCUTvlCOxmVsDiVVDmLVnmVtpiVWpmLXNmVvPiVYPmLYjmWwmiWJlmWaImMarmWy+iWLNmWcBmNczkvclmX13iXeKmNe3kSUNmXtvCXgEkLgjmYVqSXhskOhZmYr7D/mIzZCo75mKsQmZKZCpRZmc2Gma2ImJppDcWmNVvDmZ1JDbZGZ+w4mvpgaoRmkDMTM675mrAZm7I5m7RZm7Z5m7iZm7q5m7zZm775m7yJAvNBaVhRkDLTmsAJmyyAnMnpmsvZnMrJnNBZaNI5ncdpnZhWndP5nNjJj/OhmhA5cvJXbZYklvtynuYpmglRmusYmuX5nuO5bukJn41Yn+rxmWBGn+Jpn+QZn1wyn/7JKQDKn/Kpn/1JoP9poCaCngqaoAHahQO6nxLqIiggnKFQoaKAoRdqoaCgoR3KoZ/goSEKop4goqh5oiiaoiq6oq3QGFPxCRcBmptwji/KCWpj/zAfqQl5wYWUsGUGg3WagEsGw4iY0EoH4wlFZWwcUhQvAaSZEBmg8I7pKADgxAkK4DJTWqWdYF+WZqMdQaSbAEoNCQoZ46SXQGIZgZElYha3ZqVK+gnzCAqgBKZn+kpdugk+apqbcBHBhqWfsDKecDYNEAEXVyKkdhafYBegAJBR2hHqdgkXQQJqAacCkGWbYBZq2glBQ2ufQKMRQKf/waZ6ugmK2gkKaXFj2gkvYamaQKMoCAqHygkkdjQPuaVG86dTkReP+h94oReB+qaaMJEHkKqZwABXkxes6qY8OgmyJggiQayWEDQiIKQ5aglnA6qWYBNHo60u4qLVagkJA9itlTCRBiOjl3Cq6Jiod6oJwNYRw/YJDxBs31oJexMKReOoLJqv+rqv/Nqv/vqvABuwn2ETlZQxySqw8CASDGATV4aw9HARExCxbHOlHbE2AMARX2YVozSsiSGuDjsN9/oYcjarhJAxFGUwo1SpH+sNMmBxK8FlLaGFHeFNPlFxB4CtKwsN3DQBgzATJsawLgETteqsKpuz2LCzg0CxIwEBIjEBG/OQGHurRju1VFu1Vnu1WJu1Wru1XNu1Xvu1YBu2Yju2ZFu2Znu2aJu2aru2bNu2bmu1gQAAOw==);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Compared to 115 survivors of sudden cardiac death receiving conventional antiarrhythmic agents selected by electrophysiologic testing, 113 patients treated with amiodarone had a significantly greater survival free of a cardiac event including cardiac mortality, resuscitated cardiac arrest, or implanted defibrillator shock.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from The CASCADE Investigators, Am J Cardiol 1993; 72:280.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f16_42_17069=[""].join("\n");
var outline_f16_42_17069=null;
var title_f16_42_17070="Plasma concentrations C";
var content_f16_42_17070=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F81642&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F81642&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    GLP-1 concentrations (top) and GIP concentrations (bottom) using NH2-terminal assays",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 297px; height: 410px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Data are means &plusmn;SE.",
"    <div class=\"footnotes\">",
"     * p &lt;0.05 for differences between type 2 diabetic patients and healthy subjects.",
"    </div>",
"    <div class=\"reference\">",
"     Modified with permission from: Vilsboll, T, Krarup, T, Deacon, C, et al. Reduced postprandial concentrations of intact biologically active glucagon-like peptide 1 in type 2 diabetic patients. Diabetes 2001; 50:609. Copyright &copy; 2001 The American Diabetes Association.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f16_42_17070=[""].join("\n");
var outline_f16_42_17070=null;
var title_f16_42_17071="Algorithm for the treatment of HLH and MAS";
var content_f16_42_17071=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=HEME%2F65737&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=HEME%2F65737&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 542px\">",
"   <div class=\"ttl\">",
"    Algorithm for the treatment of hemophagocytic lymphohistiocytosis and macrophage activation syndrome",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 522px; height: 516px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <p>",
"     &nbsp;",
"    </p>",
"    <div class=\"footnotes\">",
"     HLH: hemophagocytic lymphohistiocytosis; MAS: macrophage activation syndrome; EBV: Epstein-Barr virus; CMV: cytomegalovirus; HIV: human immunodeficiency virus; JIA: juvenile idiopathic arthritis; HLH-94: HLH 1994 treatment protocol; CSA/Dex: treatment with cyclosporin + dexamethasone; XLP: X-linked lymphoproliferative syndrome; HCT: hematopoietic cell transplantation.",
"     <br/>",
"     * Check for mutations listed below. Since EBV, CMV, herpes, parvovirus, and many other viral infections can unmask HLH caused by one of these mutations, do NOT use presence of these infections to delay treatment with HLH-94. HCT is recommended for all patients &lt;2 years of age, those with CNS-HLH, poor response to the first eight weeks of HLH-94 (or relapse), and all those with homozygous mutations of perforin, MUNC13-4, XLP, and syntaxin genes.",
"     <br/>",
"     <span class=\"bullet\">",
"      &bull;",
"     </span>",
"     Griscelli &amp; Chediak-Higashi syndromes, XLP, Kawasaki disease. Rashes of HLH may resemble Kawasaki-type rashes. HCT is needed for the first three of these diseases and for Kawasaki disease if poor response to HLH-94.",
"     <br/>",
"     &Delta; Solid organ or bone marrow transplantation.",
"     <br/>",
"     <span class=\"lozenge\">",
"      &loz;",
"     </span>",
"     Bacterial or fungal infection, leishmaniasis, malaria.",
"     <br/>",
"     &sect;",
"     <sup>",
"     </sup>",
"     Alemtuzumab should be employed for unresponsive HLH and may allow patients to undergo HCT",
"     <sup>",
"      [1]",
"     </sup>",
"     .",
"    </div>",
"    <div class=\"reference\">",
"     Reference:",
"     <ol>",
"      <li>",
"       Marsh RA, Allen CE, McClain KL, et al. Salvage therapy of refractory hemophagocytic lymphohistiocytosis with alemtuzumab. Pediatr Blood Cancer 2012.",
"      </li>",
"     </ol>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f16_42_17071=[""].join("\n");
var outline_f16_42_17071=null;
